

International Annual Meeting on Supportive Care in Cancer

Adelaide, Australia

23-25 June 2016

Congress website: <http://www.mascc2016.kenes.com/>

Society website: <http://www.mascc.org/>

LEARNING OBJECTIVES

After participating in this educational event, learners should be able to:

- Address individual needs in compliance with their Continuous Professional Development (CPD) plan.
- Discuss and exchange the latest information in supportive care research and practice.
- Review new developments, challenges and modern technology in supportive cancer care.
- Select appropriate interventions and therapy for cancer symptoms and complications based on individual patient characteristics.
- Recognize the common symptoms and complications caused by cancer and its treatment.
- Perform an assessment of health status, symptoms and quality of life in patients with cancer.

SCIENTIFIC PROGRAMME

MASCC16 Scientific Programme

Wednesday, June 22, 2016

STUDY GROUP/MASCC MEETING: MASCC Board Meeting

08:00 - 13:30

HQ Hotel 1

OTHER: Cancer Nurse Practitioner Workshop

08:00 - 13:00

Sahmri

STUDY GROUP/MASCC MEETING: Study Group: Leadership

14:00 - 15:30

HQ Hotel 1

STUDY GROUP/MASCC MEETING: Editorial Board Meeting

15:30 - 17:00

HQ Hotel 1

PATIENT SEMINAR: Patient Seminar 1

14:00 - 17:00

HQ Hotel 2

Chair: Raelene Boyle (Australia)
Co-Chair: Jude Lees (Australia)

14:00 **Introduction**
Invited Speaker: Raelene Boyle (Australia)

14:02 Invited Speaker: Mark Schubert (USA)

14:12 Invited Speaker: Ian Hewson (Australia)

14:22 **Look good feel better?**
Invited Speaker: Jervoise Andreyev (United Kingdom)
14:32 Invited Speaker: Pam Nielsen (Australia)
14:42 Invited Speaker: Julie Kitto (Australia)

OTHER: CAC Reception

17:30 - 19:30

HQ Hotel 1

Thursday, June 23, 2016

e-Poster Presentations: Antiemetics

08:00 - 18:00

Exhibition

- 08:00 **Rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients aged <65 versus ≥65 years**
: Matti Aapro (Switzerland)
- 08:00 **NO SIGNALS OF INCREASED TOXICITY AFTER CONCOMITANT ADMINISTRATION OF NEPA WITH ETOPOSIDE OR DOCETAXEL: POOLED SAFETY DATA ANALYSIS FROM 4 PIVOTAL STUDIES**
: Matti Aapro (Switzerland)
- 08:00 **Availability of and access to medications needed for the implementation of MASCC/ESMO antiemetic guidelines in governmental hospitals in Serbia**
: Snezana Bosnjak (Serbia)
- 08:00 **GINGER IN THE MANAGEMENT OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV), IN PATIENTS RECEIVING HIGH DOSE CISPLATIN: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY**
: Paolo Bossi (Italy)
- 08:00 **CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN GYNECOLOGICAL CANCER PATIENTS: "TREATMENT-RELATED" AND "PATIENT-RELATED" RISK FACTORS**
: Letizia Carnelli (Italy)
- 08:00 **Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis**
: Leonard Chiu (Canada)
- 08:00 **Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a retrospective study**
: Leonard Chiu (Canada)
- 08:00 **Latest advances in the management of radiation-induced pain flare, nausea and vomiting**
: Nicholas Chiu (Canada)
- 08:00 **A SYSTEMATIC REVIEW OF METHODOLOGIES, ENDPOINTS AND OUTCOME MEASURES IN PHASE III RANDOMISED TRIALS OF INTERVENTIONS FOR RADIATION THERAPY-INDUCED NAUSEA AND VOMITING**
: Kristopher Dennis (Canada)
- 08:00 **DEVELOPMENT OF A PREDICTION TOOL FOR IDENTIFYING PATIENTS AT HIGH RISK FOR CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV)**
: George Dranitsaris (Canada)
- 08:00 **Randomized, placebo-controlled, phase 3 study of aprepitant in preventing chemotherapy-induced nausea and vomiting in children: analysis by age group**
: Stuart Green (USA)
- 08:00 **A STUDY TO UNDERSTAND THE BENEFITS OF YOGA IN POST CHEMOTHERAPY PHASE TOWARDS CONTROLLING OF GRADE II AND III NAUSEA AND VOMITTING**
: SHANKAR JAKHAR (India)
- 08:00 **Chemotherapy-induced nausea and vomiting : an oncology-day unit experience.**
: FLORENCE LAI-TIONG (France)
- 08:00 **Breast cancer patients' CINV experience with AC chemotherapy and guideline-consistent antiemetics**
: Jiyeon Lee (Republic of Korea)

- 08:00 **Retargeting goals for CINV management is necessary**
: Jiyeon Lee (Republic of Korea)
- 08:00 **Rolapitant for the Prevention of Nausea in Patients Receiving Moderately or Highly Emetogenic Chemotherapy**
: Rudolph Navari (USA)
- 08:00 **CHOICE OF STUDY ENDPOINT SIGNIFICANTLY IMPACTS THE RESULTS OF BREAST CANCER TRIALS EVALUATING CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING**
: Terry Ng (Canada)
- 08:00 **Rolapitant for control of chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer**
: Bernardo L. Rapoport (South Africa)
- 08:00 **EFFECTIVENESS OF FOSAPREPITANT VS APREPITANT ALONG WITH STANDARD DOSE DEXAMETHASONE AND SEROTONIN RECEPTOR ANTAGONIST IN REDUCING CINV IN PATIENTS RECEIVING HIGHLY EMETOGENIC THERAPY**
: Rakesh Roy (India)
- 08:00 **COMPARISON OF ORALLY ADMINISTERED BRAIN (HM01)- AND NON-BRAIN (HM02)-PENETRATING GHRELIN RECEPTOR AGONISTS TO PREVENT EMESIS IN SUNCUS MURINUS (HOUSE MUSK SHREW)**
: John Rudd (Hong Kong, China)
- 08:00 **QUANTITATIVE MARKET RESEARCH TO IDENTIFY FACTORS THAT INFLUENCE CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) TREATMENT COMPLIANCE**
: Pierfrancesco Ruffo (Switzerland)
- 08:00 **Trial of antiemetic triplet therapy comparing palonosetron and granisetron in breast cancer patients receiving AC chemotherapy: Double blind randomised comparative phase III study**
: Mitsue Saito (Japan)
- 08:00 **Prospective evaluation for combination antiemetic therapy on chemotherapy-induced nausea and vomiting in colorectal cancer receiving oxaliplatin-based chemotherapy**
: Mototsugu Shimokawa (Japan)
- 08:00 **MANAGING CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN HEAD AND NECK CANCER PATIENTS RECEIVING CISPLATIN CHEMOTHERAPY WITH CONCURRENT RADIATION**
: Jordan Stinson (Canada)
- 08:00 **SINGLE ASCENDING DOSE PHARMACOKINETICS OF ROLAPITANT ADMINISTERED INTRAVENOUSLY AT SUPRATHERAPEUTIC DOSES IN HEALTHY VOLUNTEERS**
: XIAODONG WANG (USA)
- 08:00 **EFFECTS OF ROLAPITANT ADMINISTERED INTRAVENOUSLY ON THE PHARMACOKINETICS OF COOPERSTOWN COCKTAIL (MIDAZOLAM, OMEPRAZOLE, WARFARIN, CAFFEINE, AND DEXTROMETHORPHAN) IN HEALTHY VOLUNTEERS**
: XIAODONG WANG (USA)
- 08:00 **EFFECTS OF ROLAPITANT ADMINISTERED INTRAVENOUSLY ON THE PHARMACOKINETICS OF DIGOXIN (P-GP) AND SULFASALAZINE (BCRP) IN HEALTHY VOLUNTEERS**
: XIAODONG WANG (USA)
- 08:00 **Strain differences in cisplatin-induced emesis in mice**
: Kouichi Yamamoto (Japan)
- 08:00 **A phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy**
: Kouichi Yokoyama (Japan)
- 08:00 **The Effect of Good CINV Management Ward (GCM-Ward) Program on CINV management in China**
: Li Zhang (China)

e-Poster Presentations: Bone

08:00 - 18:00

Exhibition

- 08:00 **Osteoporosis prevalence among breast cancer patients in Mexico City**
: Claudia Haydee Arce-Salinas (Mexico)
- 08:00 **Radiological changes on CT after stereotactic body radiation therapy to non-spine bone metastases: a descriptive series**
: Nicholas Chiu (Canada)
- 08:00 **Cbfa1-activated expression of ATF6a protein is required for chondrocyte differentiation**
: Fengjin Guo (China)
- 08:00 **EFFICACY AND SAFETY OF THE ZOLENDRONIC ACID IN THE MANAGEMENT OF BONE METASTASIS FOLLOWING RAPID INFUSION IN PATIENTS WITH COLORECTAL CANCER (CC)**
: Panagiotis Heras (Greece)
- 08:00 **The prospective study of Medication related osteonecrosis of the jaw under regular dental maintenance.**
: Ryoichi Hosokawa (Japan)
- 08:00 **A Clinical Study of Osteoradionecrosis at Our Hospital**
: Tetsuhito Konishi (Japan)
- 08:00 **QUALITY OF LIFE IN RESPONDERS AFTER PALLIATIVE RADIATION THERAPY FOR PAINFUL BONE METASTASES USING EORTC QLQ-C30 AND EORTC QLQ-BM22: RESULTS OF A BRAZILIAN STUDY**
: Lucas Mendez, MD (Brazil)
- 08:00 **REASON FOR DENTAL EXTRACTION AND OSTEONECROSIS OF THE JAW IN 17 CANCER PATIENTS, WHO RECEIVED ANTIRESORPTIVES AND/OR TARGETED THERAPY AND/OR CHEMOTHERAPY, PRELIMINARY REPORT**
: Ourania Nicolatou-Galitis (Greece)
- 08:00 **OSTEONECROSIS OF THE JAW IN A PATIENT WITH ACUTE MYELOID LEUKEMIA, WHO RECEIVED AZACITIDINE**
: Ourania Nicolatou-Galitis (Greece)
- 08:00 **Using a marker of bone remodeling PINP to assess antiresorptive properties of zoledronic acid (Zol) for bone metastases of breast cancer**
: Anton Snegovoy (Russia)

e-Poster Presentations: Cancer Pain

08:00 - 18:00

Exhibition

- 08:00 **THE FREQUENCY AND OUTCOMES OF URINE DRUG TEST AMONG ADVANCED CANCER PATIENTS ON CHRONIC OPIOID THERAPY AT AN OUTPATIENT SUPPORTIVE CARE CENTER**
: Joseph Arthur (USA)
- 08:00 **URINARY CYTOKINES/CHEMOKINES PATTERN AFTER MAGNETIC RESONANCE-GUIDED HIGH INTENSITY FOCUSED ULTRASOUND FOR PALLIATIVE TREATMENT OF PAINFUL BONE METASTASES**
: Ahmad Bushehri (Canada)
- 08:00 **Effectiveness of methadone in opioid rotation for palliative care patients**
: Amy Chang (Hong Kong, China)

- 08:00 **Extraspinal Percutaneous Osteoplasty for the Treatment of Painful Bony Metastasis**
: Eun Jung Chang (Republic of Korea)
- 08:00 **Subcutaneous access port implantation for epidural administration with patient controlled analgesia for the management of refractory cancer pain**
: Eun Jung Chang (Republic of Korea)
- 08:00 **Taxane-induced arthralgia and myalgia: a literature review**
: Nicholas Chiu (Canada)
- 08:00 **Which pain intensity scale from the Brief Pain Inventory correlates most highly with functional interference scores in patients experiencing taxane-induced arthralgia and myalgia?**
: Nicholas Chiu (Canada)
- 08:00 **Re-irradiation for painful bone metastases: Evidence-based approach**
: Nicholas Chiu (Canada)
- 08:00 **A PROSPECTIVE STUDY OF DOCETAXEL-ASSOCIATED ACUTE PAIN SYNDROME**
: Nicholas Chiu (Canada)
- 08:00 **A PROSPECTIVE MULTI-CENTRE STUDY OF INDIVIDUALISED MANAGEMENT OF BREAKTHROUGH CANCER PAIN (BTcP)**
: Andrew Davies (United Kingdom)
- 08:00 **THE BARRIERS AGAINST OPTIMAL OPIOID PRESCRIBING IN POLAND**
: Tomasz Dzierżanowski (Poland)
- 08:00 **Patient and carer experiences of pain care in a regional Australian comprehensive cancer care setting: A qualitative sub-study of the Stop Cancer PAIN Trial**
: Annmarie Hosie (Australia)
- 08:00 **The effect of negative air ion on pain in terminal cancer patients**
: Sun wook Hwang (Republic of Korea)
- 08:00 **Radiotherapy for Symptomatic Lymph Node Metastasis from Hepatocellular Carcinoma**
: Kyubo Kim (Republic of Korea)
- 08:00 **Effects of orengedokuto for advanced cancer patients with brain metastasis, brain tumor, and vertebral body metastasis.**
: TOSHIFUMI KOSUGI (Japan)
- 08:00 **Compared study of efficacy and safety between oxycodone/naloxone CR and oxycodone CR in Korean cancer pain patients**
: Kyung Hee Lee (Republic of Korea)
- 08:00 **Expectation of a decrease in pain affects the prognosis of pain in cancer patients: A prospective study of response to morphine**
: Hiromichi Matsuoka (Japan)
- 08:00 **8 GRAY SINGLE FRACTION PALLIATIVE RADIOTHERAPY IN BONE METASTASES – A SINGLE INSTITUTE EXPERIENCE**
: Tahir Mehmood (Pakistan)
- 08:00 **Knowing, gnawing and annoying cancer pain in the wards: a 2 year audit of indoor patients from a tertiary urban centre in India.**
: Mahesh Menon (India)
- 08:00 **REAL-WORLD UTILIZATION OF DARBEPOETIN ALFA IN CANCER CHEMOTHERAPY PATIENTS IN CURRENT CLINICAL PRACTICE**
: Xiaoyun Pan (USA)
- 08:00 **FACTORS INFLUENCING THE INITIATION OF STRONG OPIOIDS IN CANCER PATIENTS ON PALLIATIVE CARE: AN AUDIT FROM A TERTIARY CANCER CENTRE IN INDIA**
: Bhushan Parmar (India)
- 08:00 **Clinical Insight: Scalene Syndrome and its relevance in post mastectomy pain**
: RAGHAVENDRA RAMANJULU (India)
- 08:00 **A retrospective review of cancer patients receiving subcutaneous lignocaine infusion for pain**
: Davinia Seah (Australia)

- 08:00 **ASSESSMENT OF ADEQUACY OF PAIN MANAGEMENT IN ADVANCE CANCER PATIENTS**
: Harminder Singh (India)
- 08:00 **PAIN MANAGEMENT IN CASES OF CANCER CERVIX BY WHO STEP LADDER PROTOCOL**
: Uma Singh (India)
- 08:00 **OPIOID PHARMACOGENOMICS AND CANCER PAIN**
: PAUL WALKER (USA)
- 08:00 **Management of children with life limiting conditions in Two County hospitals Western Kenya Region**
: Pamela Were (Kenya)
- 08:00 **CUT POINTS FOR MILD, MODERATE, AND SEVERE PAIN AMONG CANCER AND NON-CANCER PATIENTS: A LITERATURE REVIEW**
: Aaron Woo (Hong Kong, China)
- 08:00 **An Exploratory Study on the Effectiveness of “Calmare Therapy” in Patients with Cancer-related Neuropathic Pain: A Pilot Study**
: Yongjae Yoo (Republic of Korea)
- 08:00 **Effect of acupoints-pressing and abdominal massage on preventing opioid induced constipation in the treatment of cancer pain**
: Fan Zu-Yan (China)

e-Poster Presentations: Education in Supportive Care

08:00 - 18:00

Exhibition

- 08:00 **The Impact of Psychological Intervention Program in Improving Psycho-Sexual Health of Married Women with Breast Cancer in Khartoum State**
: Sana Abasher (Kingdom of Saudi Arabia)
- 08:00 **IMPLEMENTING EDUCATIONAL RESOURCES INTO ROUTINE PRACTICES OF RURAL ABORIGINAL HEALTH WORKERS: THE CANCER HEALING MESSAGES FLIPCHART EXPERIENCE**
: Mia Bierbaum (Australia)
- 08:00 **Don't let me be misunderstood! Improving the chemotherapy experience for patients from CALD (culturally and linguistically diverse) backgrounds through enhanced communication**
: Deirdre D'Souza (Australia)
- 08:00 **CLINICOPATHOLOGIC PATTERN OF CERVICAL PAP SMEARS**
: Shyam Nandan Gupta (Nepal)
- 08:00 **ASSESSMENT OF PRE AND POST RT PELVIC BONE DENSITY IN PATIENTS OF GYNECOLOGICAL MALIGNANCY UNDERGOING PELVIC RADIOTHERAPY : A PILOT STUDY.**
: Divyesh Kumar (India)
- 08:00 **Impact of the Patient Education System and Follow-Up Plan for Metastatic Melanoma Patients Treated with Ipilimumab**
: Manon Lemonde (Canada)
- 08:00 **Assessing the Supportive Care Needs of Canadian Melanoma Patients and Survivors Attending an Outpatient Clinic**
: Manon Lemonde (Canada)
- 08:00 **SUPPORTIVE CARE FOR ABORIGINAL YOUTH AFFECTED BY CANCER: BUILDING UNDERSTANDING FROM NARRATIVES TO IMPROVE SERVICE PROVISION**
: Jasmine Micklem (Australia)

- 08:00 **EVALUATIONS ON ECONOMIC OUTCOMES IN BREAST CANCER PATIENTS**
: Anantha Naik Nagappa (India)
- 08:00 **The contours and cultivation of compassion: Advanced cancer patients perspectives on sympathy, empathy, and compassion and the feasibility of compassion training**
: Shane Sinclair (Canada)
- 08:00 **A Home based Palliative care and Educational Model for Supportive Care in India**
: Shiv Pratap Singh Rana (India)
- 08:00 **International Collaborators for Supportive Education Beyond Boundaries**
: Savitri Singh-carlson (USA)
- 08:00 **An Evaluation of Supportive Care Webinars for People Affected by Cancer and Health Professionals**
: Annika Smissen (Australia)
- 08:00 **Collaborative pharmacotherapy involving physicians and pharmacists aimed at improving adherence in everolimus therapy for advanced/recurrent breast cancer and its outcomes.**
: Maki Todo (Japan)
- 08:00 **Exploring factors influencing uncertainty in illness and quality of life in women undergoing breast cancer screening**
: Chihjung Wu, PhD student (Taiwan)
- 08:00 **UNDERSTANDING THE SELF-CARE EXPERIENCES OF PATIENTS WITH NASOPHARYNGEAL CARCINOMA ON MANAGING THE NUTRITION IMPACT SYMPTOM CLUSTER DURING RADIOTHERAPY**
: Wenli Xiao (Hong Kong, China)
- 08:00 **BARRIERS EXISTING IN THE MANAGEMENT OF THE NUTRITION IMPACT SYMPTOM CLUSTER IN PATIENTS WITH NASOPHARYNGEAL CARCINOMA DURING RADIOTHERAPY**
: Wenli Xiao (Hong Kong, China)
- 08:00 **Decrease in Palliative Performance Scale score during 1 week predicts survival in advanced cancer patients**
: SeokJoon Yoon (Republic of Korea)

e-Poster Presentations: Fatigue

08:00 - 18:00

Exhibition

- 08:00 **Prospective clinico-dosimetric evaluation of fatigue among head and neck cancer patients treated by Intensity modulated radiotherapy.**
: Trinanjan Basu (India)
- 08:00 **DOCETAXEL-RELATED FATIGUE IN MEN WITH METASTATIC PROSTATE CANCER, A DESCRIPTIVE ANALYSIS**
: Alice Bergin (Australia)
- 08:00 **Fatigue Management and its Effectiveness Reported by Cancer Patients: A National Survey**
: Yun-Jen Chou (Taiwan)
- 08:00 **SYMPTOMATOLOGY OF CANCER RELATED FATIGUE AND IMPACT ON QUALITY OF LIFE OF PALLIATIVE CARE PATIENTS IN A TERTIARY CANCER INSTITUTE: A PROSPECTIVE OBSERVATIONAL STUDY**
: Arunangshu Ghoshal (India)
- 08:00 **Pooled analysis of treatment-related fatigue with anti-PD-1/PD-L1 therapies in cancer patients**
: Shaodong Hong (China)

- 08:00 **GENE EXPRESSION PROFILING OF INFLAMMATION AND IMMUNE RESPONSE PATHWAYS IN ONCOLOGY PATIENTS UNDERGOING CHEMOTHERAPY WITH DISTINCT EVENING FATIGUE TRAJECTORIES**
: Kord Kober (USA)
- 08:00 **Prevalence and determinants of fatigue in patients after hematopoietic stem cell transplantation**
: Kompetenznetz KOKON (Germany)
- 08:00 **Applicability of international guidelines for cancer-related fatigue in Australia: a Delphi study**
: Elizabeth PEARSON (Australia)
- 08:00 **EXPLORATORY STUDY ON ANTI-INFLAMMATORY EFFECT BY FUCOIDAN FOR ADVANCED CANCER PATIENTS**
: HIDENORI TAKAHASHI (Japan)
- 08:00 **CANCER RELATED FATIGUE IN PATIENTS RECEIVING CHEMOTHERAPY; A SINGLE INSTITUTIONAL STUDY FROM NORTHERN INDIA**
: Vineet Talwar (India)
- 08:00 **A LONGITUDINAL STUDY OF HOPE IN WOMEN WITH EARLY STAGE BREAST CANCER AND FATIGUE**
: Inger Utne (Norway)

e-Poster Presentations: Geriatrics

08:00 - 18:00

Exhibition

- 08:00 **ASSESSMENT OF BARRIERS TO GOOD MEDICATION TAKING BEHAVIOUR IN METASTATIC PROSTATE CANCER PATIENTS RECEIVING ORAL ANTI-ANDROGEN THERAPY**
: Soha Ahrari (Canada)
- 08:00 **Breast cancer in Elderly women(>70 years): An institutional analysis from developing country**
: Gogia Ajay (India)
- 08:00 **DIALOG workshop on standardization of a minimum dataset for the geriatric assessment in oncology**
: Tristan CUDENNEC (France)
- 08:00 **An Analysis of Elderly Patients Compliance and Disease Distribution Treated with Radiation Therapy**
: Seok Ho Lee (Republic of Korea)
- 08:00 **ESTIMATING THE RISK OF SEVERE CHEMOTHERAPY TOXICITY IN ADULTS ≥65 YEARS: A STUDY COMPARING THE CARG SCORE WITH ONCOLOGISTS' ESTIMATES OF TOXICITY**
: Erin Moth (Australia)
- 08:00 **Development of Mini-Comprehensive Geriatric Assessment for the Elderly Cancer Patients Based on Relationships between Comprehensive Geriatric Assessment Items and Performance Status**
: Keon Uk Park (Republic of Korea)
- 08:00 **The Senior Toronto Oncology Panel (STOP) Study**
: Martine Puts (Canada)
- 08:00 **Factors influencing experiences and needs of informal caregivers of older cancer patients: An integrated literature review**
: Petra Stolz Baskett (Switzerland)

SATELLITE SYMPOSIUM: Satellite Symposium
(Industry Session not included in main event CME/CPD credit)

11:30 - 13:00

Hall L

e-Poster Presentations: Mucositis

08:00 - 18:00

Exhibition

- 08:00 **PHASE 1B TRIAL OF SUPEROXIDE (SO) DISMUTASE (SOD) MIMETIC GC4419 TO REDUCE CHEMORADIO THERAPY (CRT)-INDUCED MUCOSITIS (OM) IN PATIENTS (PTS) WITH ORAL CAVITY/OROPHARYNGEAL CARCINOMA (OCC)**
: Carryn Anderson (USA)
- 08:00 **PICROSIRIUS RED POLARIZATION METHOD TO EXAMINE CHRONIC CHANGES IN COLLAGEN DEPOSITION IN IRRADIATED INTESTINE**
: Emma Bateman (Australia)
- 08:00 **Potential of ST-617 to Prevent the Occurrence and Reduce the Duration of Severe Oral Mucositis**
: BJ Bormann, CEO (USA)
- 08:00 **NALOXONE ADMINISTRATION IS ASSOCIATED WITH INCREASED TUMOUR GROWTH FOLLOWING IRINOTECAN IN A RAT BREAST CANCER MODEL**
: Joanne Bowen (Australia)
- 08:00 **METHOTREXATE EFFICACY IS UNCHANGED BY NALOXONE IN A PRE-CLINICAL BREAST CANCER MODEL**
: Joanne Bowen (Australia)
- 08:00 **SELECTIVE RADIOPROTECTION WITH AMIFOSTINE IN HEAD AND NECK CANCER PATIENTS IN THE ERA OF IMRT**
: Jens Buentzel (Germany)
- 08:00 **LOW LEVEL LASER TREATMENT FOR THE MANAGEMENT OF ORAL MUCOSITIS: MECHANISMS OF ACTION, IRRADIATION PARAMETERS AND DOSE**
: James Carroll (United Kingdom)
- 08:00 **ASSESSMENT OF THYME HONEY ORAL GEL FOR THE PREVENTION OF CHEMOTHERAPY INDUCED ORAL MUCOSITIS IN PATIENTS WITH BREAST CANCER WHO ARE RECEIVING DOXORUBICIN AND CYCLOPHOSPHAMIDE**
: Elnaz Jahanbani Mazraeh (Iran)
- 08:00 **Oral cryotherapy in children receiving high dose chemotherapy to avoid mucositis - is it feasible?**
: Tove Kamsvåg Magnusson (Sweden)
- 08:00 **TNF- α inhibitor Etanercept does not alter the severity of methotrexate-induced gastrointestinal mucositis in the rat**
: Nicoline Kuiken (Netherlands)
- 08:00 **Effect of oral insulin on the severity and recovery of methotrexate-induced gastrointestinal mucositis in the rat**
: Nicoline Kuiken (Netherlands)
- 08:00 **Perception of oral mucositis symptoms and its impact on quality of life is different between doctors and their patients in Asia and Saudi Arabia**
: Heidi Liou (Singapore)
- 08:00 **No detection of Merkel cell polyomavirus in oral lichen planus: results of a prospective study in a French cohort of 22 patients**
: Marie MASSON REGNAULT (France)

- 08:00 **Effect of particle size of rebamipide crystal on the distribution in oral mucosa and the therapeutic effects against oral mucositis in rat**
: Takako Nakashima (Japan)
- 08:00 **SINGLE NUCLEOTIDE POLYMORPHISM (SNP) OF TAC 1 GENE IN PATIENTS EXPOSED TO RADIATION THERAPY FOR HEAD AND NECK CANCERS**
: Satheeshkumar PS (Kingdom of Saudi Arabia)
- 08:00 **Basic research of amitriptyline oral rinse in healthy volunteers: analgesic effect in patients with oral mucositis pain due to chemotherapy.**
: Hisako Sasaki (Japan)
- 08:00 **SEGMENT-SPECIFIC CHANGES OCCUR AT DIFFERENT TIME POINTS IN THE SMALL AND LARGE INTESTINE FOLLOWING IRRADIATION IN AN IN VIVO MODEL OF RADIOTHERAPY-INDUCED GUT TOXICITY**
: Romany Stansborough (Australia)
- 08:00 **Hangeshashinto prevents oral mucositis under chemoradiotherapy to head and neck cancer**
: Toru Tamahara (Japan)
- 08:00 **Regulation of intestinal secretory activity in an irinotecan-induced mucositis tumour bearing Dark Agouti rat model.**
: Daniel Thorpe (Australia)
- 08:00 **Neuron and glial change is associated with irinotecan-induced mucositis in a tumour bearing DA rat model**
: Daniel Thorpe (Australia)
- 08:00 **IS CRYOTHERAPY BENEFICIAL IN REDUCING THE INCIDENCE OF ORAL MUCOSITIS DURING AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN LYMPHOMA RECEIVING HIGH DOSE MELPHALAN?**
: Juan Toro (USA)
- 08:00 **Dacomitinib-induced diarrhea is not prevented by targeting excess chloride secretion with crofelemer in a rat model**
: Ysabella Van Sebille (Australia)
- 08:00 **Characterization of Pan-HER TKI-induced diarrhea with dacomitinib: targeting chloride secretion with crofelemer in vitro**
: Ysabella Van Sebille (Australia)
- 08:00 **HOST-MICROBE INTERACTIONS IN CHEMOTHERAPY-INDUCED ORAL MUCOSITIS**
: Eline Vanlancker (Belgium)
- 08:00 **5-Fluorouracil and irinotecan (SN-38) do not modulate the gut microbiome composition and activity in the absence of a host sytem**
: Eline Vanlancker (Belgium)
- 08:00 **Oral administration of amino acids cystine and theanine attenuates 5-fluorouracil-induced intestinal mucositis and diarrhea by promoting proliferation and reducing apoptosis of intestinal crypt cells**
: Junya Yoneda, Princopal Researcher (Japan)
- 08:00 **Availability of and access to interventions recommended by the MASCC/ISOO mucositis guidelines in governmental hospitals in Serbia**
: Ana Zilic (Serbia)

PARALLEL SESSION: Educational Session: How to write a manuscript for supportive care in cancer (parallel session type)

13:15 - 13:45

Hall L

- 13:15 **Introduction**
Invited Speaker: Fredrick Ashbury (Canada)

- 13:20 **The editors view**
Invited Speaker: Fredrick Ashbury (Canada)
- 13:40 **The author's view**
Invited Speaker: Ian Olver (Australia)
- 14:00 **The reviewer's view**
Invited Speaker: Jørn Herrstedt (Denmark)
- 14:20 **Discussion**
- 14:40 **Conclusion**
Invited Speaker: Fredrick Ashbury (Canada)

e-Poster Presentations: Neurological Complications

08:00 - 18:00

Exhibition

- 08:00 **Randomised double blind placebo controlled phase II trial of prolonged release melatonin for prevention of delirium in inpatients with advanced cancer**
: Meera Agar (Australia)
- 08:00 **IS OBESITY AN INDEPENDENT RISK FACTOR FOR OXALIPLATIN-INDUCED PERIPHERAL NEUROPATHY IN PATIENTS WITH COLORECTAL CANCER?**
: Soojung Ahn (Republic of Korea)
- 08:00 **CYTOKINE GENE POLYMORPHISM, PLASMA CYTOKINE CONCENTRATION AND COGNITIVE IMPAIRMENT: INTRICATE RELATIONSHIPS IN CHEMOTHERAPY-RECEIVING BREAST CANCER PATIENTS**
: Jung-woo Chae (Singapore)
- 08:00 **Herpes simplex virus encephalitis in the differential diagnosis of acute neurological symptoms in cancer patients: report of two cases**
: Nuria Chic (Spain)
- 08:00 **Determination of predictive factors associated with poor seizure control in cancer patients**
: Shereen Elazzazy (Qatar)
- 08:00 **Reframing CIPN: Primary Sensory Input and Chemotherapy Induced Peripheral Neurological Dysfunction**
: Jonathan Grunfeld (Israel)
- 08:00 **Multidisciplinary management for patients with pituitary metastasis from breast cancer**
: Nakamasa Hayashi (Japan)
- 08:00 **EVALUATION OF GABAPENTIN IN COLORECTAL CANCER PATIENTS WITH CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY**
: Panagiotis Heras (Greece)
- 08:00 **PREVENTION OF OXALIPLATIN-INDUCED NEUROTOXICITY THROUGH THE VITAMIN D PATHWAY**
: Gerald Higa (USA)
- 08:00 **Mechanisms of efficiency and resistance of estrogen modulators: A therapeutic potential tool for anticancer**
: Pardeep Kumar (India)
- 08:00 **Evaluation of tramadol / acetaminophen combination tablets in cancer patients who had the symptomatic chemotherapy induced peripheral neuropathy, phase 2 trial.**
: Daisuke Naruge (Japan)
- 08:00 **SEIZURES IN PATIENTS WITH PRIMARY BRAIN TUMORS: WHAT IS THEIR PSYCHOSOCIAL IMPACT?**
: John Shin (USA)

- 08:00 **NEUROPHYSIOLOGICAL DIFFERENCES BETWEEN PLATINUM AND TAXANE CHEMOTHERAPY**
: Stacey Tan (Singapore)
- 08:00 **MEASURING TREATMENT-INDUCED PERIPHERAL NEUROPATHY IN PATIENTS WITH CANCER: THE TREATMENT-INDUCED PERIPHERAL NEUROPATHY SCALE (TNAS)**
: Loretta Williams (USA)

PLENARY SESSION: Plenary 1: 25 Years of MASCC and future

13:45 - 15:15

Hall L

- Chair: Ian Olver (Australia)
- 13:45 **Introduction**
Invited Speaker: Ian Olver (Australia)
- 13:56 **25 Years of MASCC**
Invited Speaker: Richard Gralla (USA)
- 14:07 **25 Years of MASCC**
Invited Speaker: Matti Aapro (Switzerland)
- 14:18 **25 Years of MASCC**
Invited Speaker: Paul Hesketh (USA)
- 14:30 **25 Years of MASCC**
Invited Speaker: Jørn Herrstedt (Denmark)
- 14:41 **25 Years of MASCC**
Invited Speaker: Dorothy M. K. Keefe (Australia)
- 14:52 **25 Years of MASCC**
Invited Speaker: Dave Warr (Canada)
- 15:03 **The next 25 years of Supportive Care and MASCC**
Invited Speaker: Stephen T. Sonis (USA)

e-Poster Presentations: Neutropenia-Infections and Hematologic Toxicity

08:00 - 18:00

Exhibition

- 08:00 **OPTIMAL USE OF PEGFILGRASTIM (A LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR [G-CSF]) TO MANAGE CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA (FN) IN SOLID TISSUE TUMOURS: CONSENSUS GUIDANCE RECOMMENDATIONS**
: Matti Aapro (Switzerland)
- 08:00 **The Papaldo's hypothesis : the effectiveness of a reduced dosing of G-CSF in chemotherapy-treated patients with a low to moderate risk of febrile neutropenia (FN)**
: Georgala Aspasia (Belgium)
- 08:00 **Antimicrobial susceptibility in microbiological strains isolated from cancer patients with febrile neutropenia: data from 406 consecutive episodes in patients with non-hematological solid tumors**
: Nuria Chic (Spain)
- 08:00 **ONCOLOGY NURSE-LED PROTOCOL-BASED AMBULATORY MANAGEMENT OF LOW RISK FEBRILE NEUTROPENIA: PRELIMINARY RESULTS OF A PROSPECTIVE STUDY**
: Maria YP Choy (Hong Kong, China)

- 08:00 **SUPPORTIVE THERAPY IN MALIGNANT LYMPHOMA (ML) AND MULTIPLE MYELOMA (MM)**
: Aneta Dimitrovska (FYR Macedonia)
- 08:00 **A prospective, real-world study of chemotherapy and colony-stimulating factor (CSF) use in early-stage breast cancer (ESBC) patients at high risk for febrile neutropenia (FN)**
: Kerri Hebard-Massey (USA)
- 08:00 **RATIONAL DRUG DESIGN OF GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) FORMULATIONS: EVOLUTION FROM GLYCOSYLATION TO PEGYLATION AND GLYCOPEGYLATION**
: Daniel Kurnik (Israel)
- 08:00 **LEANING UPON INTERNATIONAL DIRECTIVES FOR OPTIMIZATION: ANEMIA. RESULTS OF THE FRENCH LIDOANEMIA-2 SURVEY**
: Vincent LAUNAY-VACHER (France)
- 08:00 **Nosocomial Infection of BK Virus Causing Hemorrhagic Cystitis among Patients in Hematology Department**
: TAKEHIKO MORI (Japan)
- 08:00 **FEBRILE NEUTROPENIA (FN) AND PEGFILGRASTIM PROPHYLAXIS IN BREAST CANCER AND NON-HODGKIN'S LYMPHOMA (NHL) PATIENTS RECEIVING HIGH (>20%) FN-RISK CHEMOTHERAPY**
: Jean Paul Salmon (Belgium)
- 08:00 **Survey of Oncology Clinic Personnel Resource Utilization Associated With Prophylactic Pegfilgrastim Administered by On-Body Injector (OBI) or Manual Injection**
: Ben Scott (USA)
- 08:00 **INFECTIONS, ANTIBIOTIC USE AND RESISTANCE PATTERNS IN PATIENTS AT AN AUSTRALIAN REGIONAL CANCER CENTRE**
: Christopher Steer (Australia)
- 08:00 **A review of the hospitalizations due to febrile neutropenia in cancer patients**
: Francisco Trinca (Portugal)
- 08:00 **Assessing the Utility and Benefit of Granulocyte-Colony Stimulating Factor (G-CSF) in Adjuvant Therapy for Stage III Colon Cancer**
: Vishal Vashistha (USA)
- 08:00 **Management of febrile neutropenia (FN) in patients with acute leukemia during chemotherapy in Japan: questionnaire analysis by the Japan Adult Leukemia Study Group (JALSG)**
: Minoru Yoshida (Japan)

PARALLEL SESSION: Parallel 1: Disparities in supportive care in cancer

15:45 - 17:15

Hall L

- Chair: David Currow (Australia)
Co-Chair: Lii Zhang (China)
- 15:45 **Introduction**
Invited Speaker: David Currow (Australia)
- 15:47 **Disparities in supportive care in cancer across the world**
Invited Speaker: David Roder (Australia)
- 16:09 **Disparities in Supportive care in cancer for Aboriginal health**
Invited Speaker: Alex Brown (Australia)
- 16:31 **Disparities in supportive care in India**
Invited Speaker: Raju Chacko (India)

- 16:53 **THE NATIONAL ABORIGINAL AND TORRES STRAIT ISLANDER CANCER FRAMEWORK**
: Isabella Wallington (Australia)
- 17:03 **Supportive Care Needs of Aboriginal people in South Australia: Gaps, Barriers, Enablers and Strategies identified in the Cancer Data and Aboriginal Disparities (CanDAD) Narratives**
: Rachel Reilly (Australia)

e-Poster Presentations: Nutrition and Cachexia

08:00 - 18:00

Exhibition

- 08:00 **Efficacy of nutritional support for terminally ill cancer patients in an inpatient hospice in Japan: A prospective observational study**
: Koji Amano (Japan)
- 08:00 **Investigation of p16 status, chemotherapy regimen and other nutrition markers for predicting gastrostomy in patients with head and neck cancer**
: Teresa Brown (Australia)
- 08:00 **A pilot study to investigate the feasibility of using 2D ultrasound to estimate gastric volumes and gastric emptying times in palliative care patients**
: Naomi Byfieldt, Ms (Australia)
- 08:00 **EVALUATION OF A DECISION AID FOR NUTRITION SUPPORT DECISIONS IN PAEDIATRIC ONCOLOGY**
: Jennifer Cohen (Australia)
- 08:00 **Harnessing Public Policy to Decrease Food Insecurity Among Cancer Patients**
: Francesca Gany (USA)
- 08:00 **NUTRITIONAL ASSESSMENT ON HOSPITALIZED PANCREATIC CANCER PATIENTS**
: Panagiotis Heras (Greece)
- 08:00 **Concurrent validity of PG-SGA Short Form, MUST and SNAQ to identify malnutrition risk in head and neck cancer inpatients**
: Harriët Jager-Wittenaar (Netherlands)
- 08:00 **A study of nutritional improvement in colorectal cancer patients with chemotherapy after nutritional therapy leading by specialized nurse teams**
: Jin-Xiang Lin, Jin-Jie Yang Meng-Qi (China)
- 08:00 **An Integrative Approach to Side Effects of Chemotherapies: 2 Case Reports.**
: Wenli Liu (USA)
- 08:00 **The attitudes, beliefs and behaviours of health professionals associated with cancer care regarding dietary supplements**
: Wolfgang Marx (Australia)
- 08:00 **A qualitative study assessing the value surgical and medical clinicians place on nutrition when managing patients with oesophageal cancer**
: Lara Mathers (Australia)
- 08:00 **PROPHYLACTIC PERCUTANEOUS ENDOSCOPIC GASTROSTOMY (PEG) TUBE PLACEMENT BEFORE CHEMORADIATION IN LOCALLY ADVANCED HEAD AND NECK CANCER PATIENTS**
: Tahir Mehmood (Pakistan)
- 08:00 **Deterioration of cachexia-related factors after first-line chemotherapy for advanced pancreatic cancer**
: Shuichi Mitsunaga (Japan)
- 08:00 **Cancer cachexia patients required longer length of hospital stay and higher medical costs during the first year of cancer treatment in advanced non-small-cell lung cancer**
: Tateaki Naito (Japan)

- 08:00 **PRE-OPERATIVE NUTRITIONAL SCREENING AND INTERVENTION IN PATIENTS WITH COLORECTAL CANCER: A SYSTEMATIC REVIEW**
: Gajen Perry (Australia)
- 08:00 **Study of Nutrition and Metabolism in cachexia due to chronic heart failure**
: Atefeh Raoufi (Iran)
- 08:00 **Baseline cytokines and symptom development in patients with head and neck cancer.**
: Benjamin Schultze, Assistant Professor (USA)
- 08:00 **typical antipsychotic olanzapine potentiates orexigenic ghrelin-induced receptor signaling: an in vitro study with cells expressing cloned human growth hormone secretagogue receptor.**
: Keita Tagami (Japan)
- 08:00 **Characterization of advanced pancreatic cancer patients showing a decrease of the skeletal muscle mass while receiving first-line chemotherapy**
: Noriatsu Tatematsu (Japan)
- 08:00 **ORAL NUTRITIONAL SUPPLEMENT: DIETITIAN PREFERENCES AND PRESCRIBING PRACTICES**
: Pauline Ui Dhuibhir (Ireland)
- 08:00 **Treatment of pancreatic insufficiency using creon in patients with advanced pancreatic cancer: a pilot study**
: Nicholas Zdenkowski (Australia)

PARALLEL SESSION: Parallel 2: Is e-communication critical to the delivery of cancer care?

15:45 - 17:15

Hall M

- Chair: Lidia Schapira (USA)
Co-Chair: Penelope Schofield (Australia)
- 15:45 **Introduction**
Invited Speaker: Lidia Schapira (USA)
- 15:47 **Scene setting: case and pilot**
Invited Speaker: Penelope Schofield (Australia)
- 16:09 **What might e-communication best practice involve**
Invited Speaker: Phyllis Butow (Australia)
- 16:31 **Telemedicine in rural and remote Australia - outreach and disparity**
Invited Speaker: Ian Olver (Australia)
- 16:53 **Patient Preferences for Three Mode of PRO administration: Interactive Voice Response, Paper, and Tablet**
: Marlene Frost (USA)
- 17:03 **TEXT MESSAGES TO EDUCATE, ENGAGE, AND MOTIVATE (TEEM TRIAL): PATIENT PERCEPTIONS OF TEXT MESSAGING TO SUPPLEMENT PATIENT COUNSELING AND IMPROVE MEDICATION ADHERENCE**
: Soha Ahrari (Canada)

e-Poster Presentations: Oral Care

08:00 - 18:00

Exhibition

- 08:00 **A BOON OF NATURE ALOEVERA AGAINST THE CURSE “RADIATION INDUCED XEROSTOMIA AND ORAL FIBROSIS**
: JITENDRA KUMAR ACHARYA (India)
- 08:00 **THE IMPORTANCE OF COORDINATION BETWEEN HEMATOLOGY AND DENTISTRY: A RETROSPECTIVE STUDY ON THE DEVELOPMENT OF BRONJ IN PATIENTS AFFECTED BY MULTIPLE MYELOMA**
: Christian Bacci (Italy)
- 08:00 **Patient-reported outcomes (PRO) in postmenopausal women with HR+ metastatic breast cancer (MBC) treated with everolimus/exemestane (EVE/EXE) and dexamethasone-based mouthwash (MW): the SWISH trial**
: Mark Chambers (USA)
- 08:00 **An observational study of the frequency of oral symptoms in patients with advanced cancer**
: Andrew Davies (United Kingdom)
- 08:00 **SALIVARY GLAND HYPOFUNCTION MEDIATED BY 5-FLUOROURACIL GENERATES INFLAMMATION AND OXIDATIVE STRESS**
: Luana Eschholz Bomfin (Brazil)
- 08:00 **Role of dental intervention in improving Quality of life for patients of oral cancer, with pain of dental origin, post radiotherapy treatment.**
: Abhishek Kandwal (India)
- 08:00 **Relationship between Oral Complications and Dental Conditions in the Patients Undergoing Anti-cancer Therapy: A Retrospective Study**
: Tomoko Kataoka (Japan)
- 08:00 **ADMISSION RATES FOR SUPPORTIVE CARE IN HEAD AND NECK PATIENTS UNDERGOING UNILATERAL OR BILATERAL NECK RADIOTHERAPY OR CHEMORADIOTHERAPY**
: Charles Kelly (United Kingdom)
- 08:00 **Relationships among malnutrition and oral functions in hospitalized cancer patients**
: Koichiro Matsuo (Japan)
- 08:00 **Bacterial substitution on the oral mucosa before and after hematopoietic cell transplantation: gene-level analysis by PCR-denaturing gradient gel electrophoresis**
: MURO MISATO (Japan)
- 08:00 **COMPARATIVE IN VITRO ANTIBACTERIAL TESTING OF POVIDONE-IODINE AND OTHER COMMERCIALLY AVAILABLE ORAL ANTISEPTICS BASED ON CURRENT EUROPEAN SUSPENSION ASSAY**
: Stefan Mueller (Singapore)
- 08:00 **COMPARATIVE IN VITRO TESTING OF POVIDONE-IODINE AND OTHER COMMERCIALLY AVAILABLE ORAL ANTISEPTICS AGAINST CANDIDA ALBICANS BASED ON CURRENT EUROPEAN SUSPENSION ASSAY**
: Stefan Mueller (Singapore)
- 08:00 **Reducing the recurrence of oral candidiasis by prolonged administration of lower dose of fluconazole during head and neck radiotherapy**
: Vinay Kumar Ramaiah (India)
- 08:00 **APPLICATION OF 5% ACETIC ACID AS A DIAGNOSTIC ADJUNCT IN THE DETECTION OF EPITHELIAL DYSPLASIA OF ORAL POTENTIALLY MALIGNANT DISORDERS**
: Jyotsna Rimal (Nepal)
- 08:00 **Prevention of everolimus/exemestane (EVE/EXE) stomatitis in postmenopausal women with HR+ metastatic breast cancer using a dexamethasone-based mouthwash (MW): results of the SWISH trial**
: Hope Rugo (USA)
- 08:00 **ACETONE ANALYSIS IN PERIOPERATIVE PATIENTS OF LUNG CANCER UNDER ORAL HYGIENE PROGRAM**
: Naoko Tanda (Japan)
- 08:00 **Smad7 blocks DNA damage in radiation-induced oral mucositis**
: Xiao-Jing Wang (USA)

08:00 **Multicenter phase II study of oral care program for patients with head and neck cancer receiving chemoradiotherapy**
: Takashi Yurikusa (Japan)

PARALLEL SESSION: Parallel 3: Care of cancer survivors – putting evidence into practice

15:45 - 17:15

Hall N

Chair: Bogda Koczwara (Australia)
Co-Chair: Tracey Doherty (Australia)
Discussant: Kevin Oeffinger (USA)

15:45 **Introduction**
Invited Speaker: Bogda Koczwara (Australia)

15:47 **The South Australian survivorship framework**
Invited Speaker: Tracey Doherty (Australia)

15:57 **Developing a survivorship monitoring tool for South Australia**
Invited Speaker: Marion Eckert (Australia)

16:07 **TrueNTH: A multicomponent approach to survivorship care for men with prostate cancer**
Invited Speaker: Patsy Yates (Australia)

16:17 **The healthy living after cancer partnership project**
Invited Speaker: Tba Tba ()

16:27 **Patient reported ranking of late symptoms after breast and prostate cancer and their influence on self initiated nutritional therapies – The Bedford Real World Study**
: Robert Thomas (United Kingdom)

16:37 **THE IMPACT OF CHEMOTHERAPY ON COGNITIVE FUNCTION: A PROSPECTIVE, LONGITUDINAL COHORT STUDY IN TESTICULAR CANCER**
: Hayley Whitford (Australia)

16:47 **Discussion**
Invited Speaker: Kevin Oeffinger (USA)

PARALLEL SESSION: Parallel 4: Young investigator Award Session

15:45 - 17:15

Hall L2

Chair: Rachel Gibson (Australia)
Co-Chair: Dave Warr (Canada)

15:45 **Introduction**
Invited Speaker: Rachel Gibson (Australia)

15:47 **High sensitive cardiac troponin T assay can reliably predict early anthracycline and trastuzumab cardiotoxicity in breast cancer patients**
: Hiromitsu Kitayama (Japan)

15:57 **TOLL-LIKE RECEPTOR 4 (TLR4)-MEDIATED TIGHT JUNCTION DISRUPTION AND DYSREGULATED ION SECRETION ARE KEY DRIVERS OF IRINOTECAN-INDUCED DIARRHOEA**
: Hannah Wardill (Australia)

- 16:07 **FRACTIONATED RADIATION INDUCES DIFFERENTIAL EXPRESSION OF MATRIX METALLOPROTEINASES IN THE COLON**
: Romany Stansborough (Australia)
- 16:17 **Differentiation of gastrointestinal toxicity associated with different nanoparticle formulations in a male Sprague Dawley rat 5-Flurouracil-induced mucositis model**
: Daniel Thorpe (Australia)
- 16:27 **A PROSPECTIVE STUDY VALIDATING THE EORTC QLQ-BM22 BONE METASTASES MODULE IN PATIENTS WITH PAINFUL BONE METASTASES**
: Srinivas Raman (Canada)
- 16:37 **Efficacy of Omega-3 (ω -3) Supplementation versus Omega-6 (ω -6) Supplementation for Reducing Cancer-related Fatigue among Breast Cancer Survivors: A URCC NCORP Randomized Controlled Trial**
: Luke Peppone (USA)
- 16:47 **MICROBIAL BIOMARKERS OF ORAL MUCOSITIS ONSET**
: Rebeca Vasconcelos, DDS, MS (USA)
- 16:57 **Improving delivery and documentation of supportive care management of cancer patient in resource-constrained developing countries**
: Vinay Kumar Ramaiah (India)
- 17:07 **A novel radiation therapy education program using the Virtual Environment for Radiotherapy Training (VERT) system**
: Yobelli Jimenez (Australia)

e-Poster Presentations: Palliative Care and End-Stage Disease

08:00 - 18:00

Exhibition

- 08:00 **TELEPHONIC COMMUNICATION IN PALLIATIVE CARE FOR BETTER MANAGEMENT OF TERMINAL CANCER PATIENTS IN RURAL WEST BENGAL - AN NGO BASED APPROACH**
: Manna Aditya (India)
- 08:00 **DIFFERENTIAL RESPONSE TO EXTERNAL BEAM RADIATION THERAPY IN THE TREATMENT OF PAINFUL BONE METASTASES**
: Michael Borean (Canada)
- 08:00 **SUPERIOR VENA CAVA SYNDROME: 3 CASES, MANY LESSONS LEARNED**
: Norman Brito-Dellan (USA)
- 08:00 **TIME TO RESPONSE (TTR): AN IMPORTANT UNDERREPORTED CLINICAL OUTCOME IN TREATMENT OF INCURABLE CANCER PATIENTS**
: Thomas Butler, Associate Professor (USA)
- 08:00 **A Study of Palliative Care Model in Thailand**
: Suchira Chaiviboontham, Dr. (Thailand)
- 08:00 **ATTITUDES OF CANCER PATIENTS' FAMILIES TOWARD ADVANCED DIRECTIVES AND DO NOT RESUSCITATION IN MAINLAND CHINA**
: Hui-ping Chen (China)
- 08:00 **THE ACCURACY OF CLINICIANS' PREDICTIONS OF SURVIVAL IN ADVANCED CANCER: A REVIEW**
: Stephanie Cheon (Canada)
- 08:00 **PREDICTIVE MODELS FOR SURVIVAL IN ADVANCED CANCER: A SYSTEMATIC REVIEW**
: Stephanie Cheon (Canada)
- 08:00 **Lack of concordance between patients and their non-professional carers on performance status**
: Andrew Davies (United Kingdom)

- 08:00 **Symptom Clusters and Pain in Advanced Lung Cancer**
: Mellar Davis (USA)
- 08:00 **RAPID ACCESS PALLIATIVE RADIATION THERAPY PROGRAMS; A LITERATURE REVIEW**
: Kristopher Dennis (Canada)
- 08:00 **Symptom relief in dying cancer patients – how good are we?**
: Farah Farooq (Denmark)
- 08:00 **Understanding perspectives on spiritual care: comparing and contrasting patient and health care practitioner views**
: Margaret Fitch (Canada)
- 08:00 **Integration of early palliative care in oncology treatment pathways: Guidelines of the French supportive care association**
: Aline HENRY (France)
- 08:00 **Parent's Perspectives on the End of life Care of their Cancer Child – Indian perspective**
: Julius X Scott James Martin (India)
- 08:00 **Symptom Burden and Distress in Patients with Cancer in Africa**
: Weru John (Kenya)
- 08:00 **INTRANASAL VINEGAR AS THE EFFECTIVE TREATMENT FOR PERSISTENT HICCUPS IN A PATIENT WITH ADVANCED CANCER PATIENT UNDERGOING PALLIATIVE CARE: A CASE REPORT**
: Jun Kako (Japan)
- 08:00 **ESTABLISHING A BINARY CUT-OFF POINT FOR THE PHYSICAL SCORES OF EDMONTON SYMPTOM ASSESSMENT SYSTEM-REVISED JAPANESE VERSION**
: Jun Kako (Japan)
- 08:00 **Effectiveness of Teleconsultation Service for Terminal Cancer Patients**
: Myoung Hee Kang (Republic of Korea)
- 08:00 **AYAS TRANSITIONING FROM ACTIVE TO PALLIATIVE CARE: THE EXPERIENCE OF PROFESSIONALS SUPPORTING THE PROCESS.**
: Daniel Kelly (United Kingdom)
- 08:00 **A BITTER MOUTHFUL TO SWALLOW? DIFFERENCES BETWEEN OPTIMAL AND ACTUAL SPEECH-LANGUAGE PATHOLOGY CARE OF PALLIATIVE PATIENTS WITH CANCER**
: Katherine Kelly (Australia)
- 08:00 **Symptom clusters in advanced cancer patients receiving palliative chemotherapy**
: Jiyeon Lee (Republic of Korea)
- 08:00 **A Meta-Summary on The Needs or Challenge of Terminal Cancer Patients' Family Caregivers**
: Chwen-Mei Lin (Taiwan)
- 08:00 **KEY BARRIERS AND FACILITATORS TO QUALITY END-OF-LIFE CARE FOR TERMINALLY-ILL PATIENTS IN THE PHILIPPINES**
: Maria Fidelis Manalo (Philippines)
- 08:00 **EVALUATION OF PHYSICAL SYMPTOMS USING THE EDMONTON SYMPTOM ASSESSMENT SYSTEM-REVISED JAPANESE VERSION AND BINARY DATA**
: Kobayashi Masamitsu (Japan)
- 08:00 **FAMILY CONFERENCE AT INITIAL DIAGNOSIS OF INCURABLE CANCER IN St. VINCENT's HOSPITAL**
: Ji young Mok (Republic of Korea)
- 08:00 **End-of-Life Care in Africa: A different methodology based on family-centred approach to supporting patient's care within Palliative Care in Rwanda**
: Christian Ntirimira, Palliative Care Educ (Rwanda)
- 08:00 **IMPACT OF THE CONCEPT OF PALLIATIVE CARE AMONG CANCER PATIENTS IN LOW AND MIDDLE INCOMES COUNTRIES: RWANDA PUBLIC HEALTH EXPERIENCES AS A POST GENOCIDE SOCIETY**
: Christian Ntirimira, Palliative Care Educ (Rwanda)

- 08:00 **'URINARY SYMPTOMS AND CATHETERISATION AS PART OF BLADDER CARE IN PALLIATIVE CARE INPATIENTS' – A PROSPECTIVE DUAL SITE COHORT STUDY**
: Riona Pais (Australia)
- 08:00 **DECISION OF PALLIATIVE CHEMOTHERAPY IN CANCER LATE STAGE : THE DOCTOR PATIENT RELATIONSHIP AND THE DECISION MAKING PROCESS AS SEEN BY ONCOLOGIST**
: Marie Pechard (France)
- 08:00 **Cancer patients' experiences of symptoms at the end of life from point-of-care clinical assessment data: a retrospective analysis**
: Karen Quinsey (Australia)
- 08:00 **PROACTIVE PALLIATIVE CARE IN THE INTENSIVE CARE UNIT**
: Lisa Rodger (Canada)
- 08:00 **New strategy and challenge in treatment of terminal stage pancreatic and lung cancer: herbal extracted medicines in supportive care**
: Pu Rong (China)
- 08:00 **SANN- JOONG-KUEY -JIAN -TANG inhibit human gastric cancer AGS cells through decreasing Bcl-2, Bcl-xl, Mcl-1, TCTP but increasing Bax, Caspase-9 and Caspase-3 protein expression**
: Chin Cheng Su (Taiwan)
- 08:00 **CANCER PATIENTS' NEED FOR PALLIATIVE CARE ESTIMATED ON HOSPITAL ADMISSIONS IN THE LAST YEAR OF LIFE**
: Elena Vvedenskaia (Russia)
- 08:00 **PALLIATIVE SEDATION (PS) FOR EXISTENTIAL DISTRESS (ED): A CONTROVERSY**
: PAUL WALKER (USA)
- 08:00 **AN INTEGRATIVE REVIEW ON THE ATTITUDES TOWARDS ADVANCE DIRECTIVES AND END-OF-LIFE DECISIONS OF THE WELL COMMUNITY, PATIENTS SUFFERING FROM LIFE-LIMITING ILLNESSES AND THEIR CAREGIVERS**
: Wenli Xiao (Hong Kong, China)

PARALLEL SESSION: Parallel 29: Making meaning, making special: exploring the role of the arts in cancer care

15:45 - 17:15

Hall L3

Chair: Tba Tba ()

- 15:45 **Making meaning, making special: exploring the role of the arts in cancer care**
: Sally Francis (Australia)
- 15:45 **Making meaning, making special: exploring the role of the arts in cancer care**
: Christine Putland (Australia)
- 15:45 **Making meaning, making special: exploring the role of the arts in cancer care**
: John Blines (Australia)

PARALLEL SESSION: Parallel 5: Supportive care from the patient expert perspective

17:30 - 19:00

Hall L

Chair: Sanchia Aranda (Australia)

Co-Chair: Tba Tba ()

- 17:30 **Introduction**
Invited Speaker: Sanchia Aranda (Australia)
- 17:32 **TBA**
Invited Speaker: Mark Schubert (USA)
- 17:54 **R-CHOP not so easy on the receiving side**
Invited Speaker: Ian Hewson (Australia)
- 18:16 Invited Speaker: Pam Nielsen (Australia)
- 18:38 **Feasibility, acceptability and impact of a pro-active telephone-based intervention to improve toxicity management during chemotherapy for early stage breast cancer**
: Monika Krzyzanowska (Canada)
- 18:48 **Patient Reported Outcome Measurement: Systematic Symptom Assessment in Cancer Care – Ontario Healthcare Professionals' Attitudes, the Edmonton Symptom Assessment System (ESAS) and the Road Ahead**
: Christopher Klinger (Canada)

PARALLEL SESSION: Parallel 6: Maintaining bone health in cancer (Bone Study Group)

17:30 - 19:00

Hall M

- Chair: Ourania Nicolatou-Galitis (Greece)
Co-Chair: Cesar Migliorati (USA)
- 17:30 **Introduction**
Invited Speaker: Ourania Nicolatou-Galitis (Greece)
- 17:32 **Cancer Bone microenvironment: how to maintain and how to improve an ongoing challenge**
Invited Speaker: Winston Tan (USA)
- 17:49 **Osteonecrosis post cancer therapy**
Invited Speaker: Alastair Goss (Australia)
- 18:06 **New treatments for chemotherapy-induced bone loss**
Invited Speaker: Cory Xian (Australia)
- 18:23 **Bone-targeted-therapy: treating bone pain and improving quality of life in patients with bone metastases**
Invited Speaker: Diel Ingo (Germany)
- 18:40 **Personalization supportive care (correction of anemia, neutropenia, and the appointment of bone-modifying agents)**
: Anton Snegovoy (Russia)
- 18:50 **Medication-Related Osteonecrosis of the Jaw in Advanced Cancer Patients: A Multicenter Case Registry Study**
: Deborah P. Saunders (Canada)

PARALLEL SESSION: Parallel 7: e-Poster session

17:30 - 19:00

Hall N

Chair: Sharon Elad (USA)
Co-Chair: Raj Lalla (USA)

- 17:30 **CREAM: Nursing Principles for an Oncodermatology Clinic Dedicated to Managing Dermatologic Adverse Events to Anticancer Therapy**
: Kathryn Ciccolini (USA)
- 17:40 **Coping strategies, trajectories and their associations with patient-reported outcomes among women with ovarian cancer**
: Vanessa Beesley (Australia)
- 17:50 **BREAKING DOWN THE MEDICATION COUNSELLING SESSION: PATIENT EXPERIENCES WITH AN ALTERNATIVE APPROACH TO MEDICATION COUNSELLING FOR ORAL ANTI-CANCER THERAPIES**
: Soha Ahrari (Canada)
- 18:00 **Comparing Perspectives of Men with Prostate Cancer and Health Care Professionals about Active Surveillance**
: Margaret Fitch (Canada)
- 18:10 **THE IMPACT OF AN EDUCATIONAL PROGRAM ON PATIENT PRACTICES ON SAFE USE, STORAGE, AND DISPOSAL OF OPIOIDS IN A COMPREHENSIVE CANCER CENTER**
: Maxine De la cruz (USA)
- 18:20 **Results of educational program of "Supportive care in Oncology" in Russia**
: Anton Snegovoy (Russia)
- 18:30 **Developing National Indicators to Measure Progress in Person-Centred Cancer Care**
: Margaret Fitch (Canada)
- 18:40 **Impact evaluation of cancer information and support services in Australia, UK and USA**
: Clare Sutton (Australia)
- 18:50 **EVALUATING THE COST EFFECTIVENESS OF SHARED FOLLOW-UP CARE FOR EARLY BREAST CANCER IN AUSTRALIA**
: Carolyn Der Vartanian (Australia)

e-Poster Presentations: Skin toxicity

08:00 - 18:00

Exhibition

- 08:00 **LOW LEVEL LASER THERAPY IN THE TREATMENT OF CHEMO-INDUCED GRADE III PALMAR-PLANTAR ERYTHRODYSESTHESIA**
: Sofiya Latifyan (Belgium)
- 08:00 **SCALP COOLING AS A PREVENTIVE METHOD OF CHEMOTHERAPY-INDUCED ALOPECIA: EXPERIENCE OF A PRIVATE CLINIC IN SAO PAULO, BRAZIL**
: Giselle Silva (Brazil)
- 08:00 **DIFFERENTIAL GENE EXPRESSION IN ELROTINIB-TREATED FIBROBLASTS**
: Karen Wickersham, PhD, RN (USA)

PARALLEL SESSION: Parallel 8: Systematic review: update and outcomes measures (Oral Care Study Group)

17:30 - 19:00

Hall L2

Chair: Deborah P. Saunders (Canada)

Co-Chair: Siri Beier Jensen (Denmark)

- 17:30 **Introduction**
Invited Speaker: Deborah P. Saunders (Canada)
- 17:32 **Updates in MASCC/ISOO collaboration with ASCO in guideline development**
Invited Speaker: Doug Peterson (USA)
- 17:40 **Guideline update on the oral complications in cancer therapy**
Invited Speaker: Deborah P. Saunders (Canada)
- 18:05 **Guideline update on the oral complications in cancer therapy A Bit About Spit: What We Know About Radiation and Xerostomia, IMRT and Parotid Sparing**
Invited Speaker: John Wu (Canada)
- 18:30 **Dental Disease and Dental Treatment Prior to Hematopoietic Stem Cell Transplantation (HCST): OraStem Study**
: Mike Brennan (USA)
- 18:40 **MOLECULAR CHARACTERISTICS OF CONSECUTIVE ORAL MUCOSA BIOPSIES FOLLOWING HIGH DOSE MELPHALAN TREATMENT OF MULTIPLE MYELOMA PATIENTS**
: Mette Marcussen (Denmark)
- 18:50 **Conclusion**
Invited Speaker: Deborah P. Saunders (Canada)

e-Poster Presentations: Toxicity of Targeted Anti-Cancer Therapy

08:00 - 18:00

Exhibition

- 08:00 **TOXICITIES OF THE ANTI-PD-1 IMMUNE CHECKPOINT ANTIBODY NIVOLUMAB IN THE ACUTE INPATIENT SETTING**
: Norman Brito-Dellan (USA)
- 08:00 **BLEEDING AND WOUND HEALING RISKS DURING RAMUCIRUMAB THERAPY FOR METASTATIC GASTRIC CANCER**
: Danielle Duva (USA)
- 08:00 **THE ADVERSE EFFECTS OF ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER: AT WHAT COST AND IS EXERCISE THE PANACEA?**
: Kim Edmunds (Australia)
- 08:00 **MANAGEMENT OF IMMUNE-MEDIATED HEPATITIS FROM NIVOLUMAB (clinical case)**
: Inessa Kononenko (Russia)
- 08:00 **Efficacy of intraperitoneal chemotherapy combined with systemic chemotherapy for serosa-involved colorectal cancer**
: Zhuo Liu (China)
- 08:00 **HYPERTENSION AND PROTEINURIA RISKS DURING RAMUCIRUMAB THERAPY FOR METASTATIC GASTRIC CANCER**
: Holly MARTIN (USA)
- 08:00 **A double blind randomized trial of prophylactic topical application of vitamin K1 cream for cetuximab-related skin toxicity: a self-controlled trial**
: Michiaki Nakajo (Japan)

Friday, June 24, 2016

SATELLITE SYMPOSIUM: Satellite Symposium *(Industry Session not included in main event CME/CPD credit)*

08:00 - 09:00

Hall L

STUDY GROUP/MASCC MEETING: SG1

08:00 - 09:00

Hall N

STUDY GROUP/MASCC MEETING: SG2

08:00 - 08:00

Hall L2

STUDY GROUP/MASCC MEETING: SG3

08:00 - 09:00

Hall L3

PARALLEL SESSION: Parallel 9: Nausea is the new black: innovative antiemetics

09:00 - 10:30

Hall L

Chair: Lawrence Einhorn (USA)

Co-Chair: Tba Tba ()

09:00 Introduction

Invited Speaker: Lawrence Einhorn (USA)

09:02 Introduction to nausea

Invited Speaker: Lawrence Einhorn (USA)

09:20 Nausea and related symptoms

Invited Speaker: Alex Molasiotis (Hong Kong, China)

09:40 Nausea as the primary endpoint

Invited Speaker: Patsy Yates (Australia)

- 10:00 **Nausea as a symptom cluster**
Invited Speaker: Ian Olver (Australia)
- 10:20 **RESULTS OF A SURVEY OF ONCOLOGY NURSES
ASSESSING PRACTICE PATTERNS FOR PREVENTION OF
CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV)
AND ADHERENCE TO ANTIEMETIC GUIDELINES**
Invited Speaker: Rebecca Clark-Snow (USA)

PARALLEL SESSION: Parallel 10: Geriatric assessment as a supportive care strategy in older adults with cancer

09:00 - 10:30

Hall M

- Chair: Christopher Steer (Australia)
Co-Chair: Martine Extermann (USA)
- 09:00 **Introduction**
Invited Speaker: Christopher Steer (Australia)
- 09:02 **Geriatric assessment: why bother?:**
Invited Speaker: Martine Extermann (USA)
- 09:24 **Geriatric assessment in oncology; how can it be done in
clinical practice and models of care from around the world**
Invited Speaker: Nimit Singhal (Australia)
- 09:46 **Geriatric assessment; a nurse led supportive care strategy**
Invited Speaker: Jane Philips (Australia)
- 10:08 **Consequences of informal caregiving to an older person
with cancer**
: Petra Stolz Baskett (Switzerland)
- 10:18 **Development and validation of an instrument to identify
cardiometabolic predictors of mortality in older individuals
with cancer.**
: Bogda Koczwara (Australia)

PARALLEL SESSION: Parallel 11: Education and communication study group and palliative care study groups

09:00 - 10:30

Hall N

- Chair: Fran Boyle (Australia)
Co-Chair: Sanchia Aranda (Australia)
- 09:00 **Introduction**
Invited Speaker: Fran Boyle (Australia)
- 09:02 **Enhancing cancer consultations**
Invited Speaker: Martin Tattersall (Australia)
- 09:24 **Communicating cancer risk and treatment benefits to the
public**
Invited Speaker: Sanchia Aranda (Australia)
- 09:46 **Handling uncertainty in clinical practice**
Invited Speaker: Lidia Schapira (USA)

- 10:08 **Referral Criteria for Outpatient Palliative Cancer Care: An International Consensus**
: David Hui (USA)
- 10:18 **COMPARING PALLIATIVE CARE AND SUPPORTIVE CARE SPECIALIST BELIEFS ABOUT SPIRITUAL CARE**
: Megan Best (Australia)

PARALLEL SESSION: Parallel 12: Infection and immune reactions in checkpoint and PD1 inhibition (Neutropenia, Infection-Myelosuppression Study Groups)

09:00 - 10:30

Hall L2

- Chair: Bernardo L. Rapoport (South Africa)
Co-Chair: Jean Klastersky (Belgium)
- 09:00 **Introduction**
Invited Speaker: Bernardo L. Rapoport (South Africa)
- 09:02 **Past, present and future of immunotherapy in cancer**
Invited Speaker: Tba Tba ()
- 09:24 **Immune complications (excluding skin) associated with checkpoint and PD1 inhibition**
Invited Speaker: Bernardo L. Rapoport (South Africa)
- 09:46 **dermatological complications with checkpoint and PD1 inhibition**
Invited Speaker: Vincent Sibaud (France)
- 10:08 **Characterization of Pan-HER tyrosine kinase inhibitor-induced diarrhea using a rat model**
: Ysabella Van Sebille (Australia)
- 10:18 **Clinical Characteristics of Ipilimumab-Associated Colitis. Presentation of clinical cases and toxicity management.**
: Bernardo L. Rapoport (South Africa)

PARALLEL SESSION: SG4

09:00 - 10:00

Hall L3

e-Poster Discussion: Session 1

09:00 - 10:30

Exhibition

- Chair: Sharon Elad (USA)
Co-Chair: Raj Lalla (USA)
- 09:00 **ORAL MICROBIOME CHANGES IN PEDIATRIC PATIENTS UNDERGOING CONDITIONING THERAPY FOR HEMATOPOIETIC STEM CELL TRANSPLANT**
: Catherine Hong (Singapore)

- 09:09 **Long-term childhood cancer survivors' and parents' information needs: implications for survivorship models of care**
: Janine Vetsch (Switzerland)
- 09:18 **BARRIERS TO SURVIVORSHIP FOLLOW-UP CARE WITH A PRIMARY CARE PHYSICIAN: IMPLICATIONS FOR MODELS OF CHILDHOOD CANCER SURVIVORSHIP CARE**
: Christina Signorelli (Australia)
- 09:27 **Levels and predictors of distress and unmet psychosocial needs in AYA offspring of cancer patients and the impact of a Psychosocial Assessment and Review Process**
: Adam Walczak (Australia)
- 09:36 **PATIENTS' OPINIONS ON POTENTIAL FEATURES OF AN ORAL ANTICANCER MEDICATION ADHERENCE APP**
: Eskinder Eshetu Ali (Singapore)
- 09:45 **FACTORS CORRELATING WITH SHORTER SURVIVAL AFTER TREATMENT: AIDING ONCOLOGISTS TO CHOOSE WHO (NOT) TO RECEIVE PALLIATIVE SYSTEMIC THERAPY**
: Pui Ying Patty Ho (Hong Kong, China)
- 09:54 **A Feasibility Trial of Geriatric Assessment and Integrated Care Plan for Older Cancer Patients**
: Martine Puts (Canada)
- 10:03 **Health behaviours in survivors of childhood cancer: modifiable risk factors for developing late effects**
: Joanna Fardell (Australia)
- 10:12 **Electrocardiographic finding change in advanced cancer patients**
: Takuya Oyakawa (Japan)
- 10:21 **IMPACT OF CANCER PAIN ON QUALITY OF LIFE FOR ASIAN CANCER PATIENTS AND PROGNOSTIC FACTORS FOR ACTIVITIES OF DAILY LIVING**
: Dora You (Singapore)

PLENARY SESSION: Plenary 2: Gastrointestinal toxicity management

11:00 - 12:30

Hall L

Chair: Dorothy M. K. Keefe (Australia)

Co-Chair: Richard Logan (Australia)

- 11:00 **Introduction**
Invited Speaker: Dorothy M. K. Keefe (Australia)
- 11:02 **Chemo- and radiotherapy -induced gastrointestinal toxicity**
Invited Speaker: Jervoise Andreyev (United Kingdom)
- 11:31 **Radiotherapy -induced gastrointestinal toxicity**
Invited Speaker: Eric Yeoh (Australia)
- 12:00 **Oral toxicity following cancer therapies**
Invited Speaker: Richard Logan (Australia)

SATELLITE SYMPOSIUM: Satellite Symposium
(Industry Session not included in main event CME/CPD credit)

12:30 - 14:00

Hall L

SATELLITE SYMPOSIUM: Satellite Symposium
(Industry Session not included in main event CME/CPD credit)

12:30 - 14:00

Hall M

STUDY GROUP/MASCC MEETING: SG5

12:30 - 14:00

Hall L2

STUDY GROUP/MASCC MEETING: SG6

12:30 - 14:00

Hall L3

PARALLEL SESSION: Parallel 13: Dysbiosis in the gut: what is it and what does it mean for cancer patients? (Mucositis Study Group)

14:00 - 15:30

Hall L

Chair: Paolo Bossi (Italy)

Co-Chair: Karis Cheng (Singapore)

14:00 Introduction

Invited Speaker: Paolo Bossi (Italy)

14:02 Markers for chemotherapy induced mucosal barrier injury in cancer patients

Invited Speaker: Wim Tissing (Netherlands)

14:24 Toll-like receptor 4 signalling: is this the common biological mechanism of regimen-related toxicities?

Invited Speaker: Rachel Gibson (Australia)

14:46 Probiotics to prevent gastrointestinal toxicity from cancer therapy: an interpretive review and call to action

Invited Speaker: Matthew Ciorba (USA)

15:08 THE SELECTIVE GLUCAGON-LIKE PEPTIDE-2 (GLP-2) RECEPTOR AGONIST, ELSIGLUTIDE, IS EFFECTIVE IN

INHIBITING LAPATINIB-INDUCED DIARRHOEA IN AN ESTABLISHED RAT MODEL.

: Bronwen Mayo (Australia)

15:18 Investigating lapatinib-induced diarrhoea in a tumour-bearing rat model

: Wan Nor Izzah Wan Mohamad Zain (Malaysia)

PARALLEL SESSION: Parallel 14: Cardiac toxicity

14:00 - 15:30

Hall M

Chair: Michael Ewer (USA)

Co-Chair: Tba Tba ()

14:00 Introduction

Invited Speaker: Michael Ewer (USA)

14:02 Moving knowledge from clinical trial to clinic patients: confidences and caveats for the supportive care physician

Invited Speaker: Tba Tba ()

14:24 Clinical aspects of cardiotoxicity prevention: can new understanding make concerns about cardiotoxicity obsolete

Invited Speaker: Edward Yeh (USA)

14:46 Primary and secondary cardiac events; why can we give some cardiotoxic drugs for years with little concern

Invited Speaker: Michael Ewer (USA)

15:08 THE VICTORIAN CANCER PATIENT EXPERIENCE SURVEY: ASSESSING EXPERIENCE ALONG THE CANCER PATHWAY

: Spiridoula Galetakis (Australia)

15:18 Cancer and cardio-metabolic illness in elderly cancer survivors – a secondary analysis of the Australian Longitudinal Study of Ageing

: Bogda Koczwara (Australia)

PARALLEL SESSION: Parallel 15: Dyspnoea (Palliative Care and Respiratory Study Groups)

14:00 - 15:30

Hall N

Chair: Matti Aapro (Switzerland)

Co-Chair: Tba Tba ()

14:00 Introduction

Invited Speaker: Matti Aapro (Switzerland)

14:02 opioids and steroids

Invited Speaker: David Currow (Australia)

14:24 Beyond oxygen: non-invasive ventilation and high flow oxygen

Invited Speaker: David Hui (USA)

14:46 Pulmonary rehabilitation: processes and outcomes

Invited Speaker: Vicki Shannon (USA)

15:08 IMPACT OF ONCOLOGISTS' ATTITUDES TOWARD END-OF-LIFE CARE ON PATIENT'S ACCESS TO PALLIATIVE CARE:

UNDERSTANDING TYPE I VERSUS TYPE II ONCOLOGISTS

: David Hui (USA)

15:18 PREVALENCE AND INTENSITY OF DYSPNEA IN ADVANCED CANCER AND ITS IMPACT ON QUALITY OF LIFE

: Anuja Damani (India)

PARALLEL SESSION: Parallel 16: e-Poster session

14:00 - 15:30

Hall L2

Chair: Charles Loprinzi (USA)

Co-Chair: Tba Tba ()

14:00 Adverse Event (AE) Attribution in Symptom Intervention Trials

: Jennifer Le-Rademacher (USA)

14:10 PREVALENCE OF DEMENTIA AND MILD COGNITIVE IMPAIRMENT IN OLDER CANCER PATIENTS WITH SOLID TUMOR CANCERS

: Beatrice Edwards (USA)

14:20 MINIMAL CLINICALLY IMPORTANT DIFFERENCES IN THE EORTC QLQ-BM22 AND EORTC QLQ-C15-PAL MODULES IN PATIENTS WITH BONE METASTASES

: Srinivas Raman (Canada)

14:30 10-YEAR TRENDS IN UNPLANNED READMISSION AND SURVIVAL RATES AMONG PATIENTS WITH GASTROINTESTINAL CANCER

: Joanna-Grace Manzano (USA)

14:40 OSTEOPOROSIS, LOW BONE MASS, AND RISK FACTORS FOR FRACTURES IN OLDER CANCER PATIENTS

: Beatrice Edwards (USA)

14:50 INCIDENCE OF BONE METASTASES IN US PATIENTS WITH SOLID TUMORS

: Sally Wade (USA)

15:00 "What is the role of comorbidity, frailty and functional status in treatment decision-making for older cancer patients and their family members, oncologists, and family physician?"

: Martine Puts (Canada)

15:10 POINT OF CARE CLINICAL DECISION SUPPORT FOR CANCER SYMPTOM MANAGEMENT: RESULTS OF A GROUP RANDOMIZED TRIAL.

: Janet Abrahm (USA)

15:20 Is there any relationship between chemotherapy toxicities and sociodemographic parameters of cancer patients? A question and an answer from the Turkey: single center experience

: OZLEM DOGAN (Turkey)

STUDY GROUP/MASCC MEETING: SG7

14:00 - 15:00

Hall L3

e-Poster Discussion: Session 2

14:00 - 15:30

Exhibition

Chair: Charles Loprinzi (USA)

- 14:00 **Nicotinamide adenine dinucleotide: A new therapeutic option for attenuating for cisplatin-associated adverse effects.**
: Hongseob So (Republic of Korea)
- 14:09 **The gut hormones glucagon-like peptides 1 and 2 (GLP-1 and GLP-2) are essential for the intestinal recovery after chemotherapy**
: Rasmus Hytting-Andreasen, MSc. PhD. stud (Denmark)
- 14:18 **INCIDENCE OF HYPOMAGNESEMIA IN COLORECTAL, HEAD AND NECK, AND GYNECOLOGICAL CANCER PATIENTS RECEIVING ENDOTHELIAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR OR PLATINUM AGENT: A RETROSPECTIVE ANALYSIS**
: Jordan Stinson (Canada)
- 14:27 **Oral administration of the amino acids cystine and theanine attenuates adverse events of adjuvant chemotherapy S-1 in gastrointestinal cancer patients**
: Takashi Tsuchiya (Japan)
- 14:36 **TIME TRENDS IN G-CSF PRIMARY PROPHYLAXIS AND FEBRILE NEUTROPENIA RISK AMONG WOMEN RECEIVING ADJUVANT CHEMOTHERAPY FOR EARLY-STAGE BREAST CANCER IN THE UNITED STATES**
: Ravi Goyal (USA)
- 14:45 **CHARACTERISATION OF BREAKTHROUGH PAIN IN AN AUSTRALIAN COHORT OF CANCER PATIENTS**
: Odette Spruyt (Australia)
- 14:54 **eviQ Cancer Treatments Online (www.eviQ.org.au) - providing leadership in the right choice of treatment for the right patients**
: Lisa King (Australia)
- 15:03 **A SINGLE-DOSE BIOEQUIVALENCE STUDY OF ROLAPITANT FOLLOWING ORAL AND INTRAVENOUS ADMINISTRATION IN HEALTHY VOLUNTEERS**
: XIAODONG WANG (USA)
- 15:12 **The multicenter, prospective observational study on prophylaxis of low emetic chemotherapy-induced nausea and vomiting**
: Toshinobu Hayashi (Japan)
- 15:21 **Patterns and severity of chemotherapy-induced nausea (CIN) in patients with various cancers associated with highly to moderately emetogenic chemotherapy (HEC and MEC).**
: Keisuke Aiba (Japan)

PARALLEL SESSION: Parallel 17: Models of nutritional care in high risk cancer groups

16:00 - 17:30

Hall L

Chair: Liz Isenring (Australia)

Co-Chair: Tba Tba ()

16:00 Introduction

Invited Speaker: Liz Isenring (Australia)

16:02 Implementing a best practice model of care for nutritional management of head and neck cancer: translating evidence into practice

Invited Speaker: Merran Findlay (Australia)

16:19 Nutritional risk in lung cancer: is medical nutrition therapy effective

Invited Speaker: Nicole Kiss (Australia)

16:36 Healthy living after cancer: a nationwide approach to improving dietary intake and increasing physical activity for cancer survivors

Invited Speaker: Anna Boltong (Australia)

16:53 Managing malnutrition in cancer: highlights of state-wide collaborations in Victorian health services

Invited Speaker: Jenelle Loeliger (Australia)

17:10 Comparing the effectiveness of ferric carboxymaltose and oral iron in treatment of chronic iron deficiency anemia in colon cancer patients

: Tayeb Ramim (Iran)

17:20 Muscle loss and prognosis of end-of-life breast cancer patients: Breast cancer patients in end-of-life become Cancer cachexia

: Yoshiko Kubo (Japan)

PARALLEL SESSION: Parallel 18: Supportive care in the Asia-Pacific region

16:00 - 17:30

Hall M

Chair: Ian Olver (Australia)

Co-Chair: Alex Molasiotis (Hong Kong, China)

16:00 Introduction

Invited Speaker: Ian Olver (Australia)

16:02 Cancer supportive care in Papua New Guinea

Invited Speaker: Dadi Toka (Papua New Guinea)

16:24 Cancer supportive care in China

Invited Speaker: Lii Zhang (China)

16:46 Cancer supportive care in Singapore and Hong Kong

Invited Speaker: Karis Cheng (Singapore)

17:08 THE PHARMACOGENOMICS OF CHEMOTHERAPY-INDUCED TOXICITIES: AN UMBRELLA REVIEW OF SYSTEMATIC REVIEWS AND META-ANALYSES

: Jared Campbell (Australia)

17:18 DIFFERENCES IN GENETIC LOCI PREDICTIVE OF CHEMOTHERAPY-INDUCED GASTROINTESTINAL TOXICITY

(CGIT) RISK IN PATIENTS RECEIVING 5-FLUOROURACIL IN INDEPENDENT COHORTS

: Janet Collier (Australia)

PARALLEL SESSION: Parallel 19: Delirium in advanced cancer: state of the science

16:00 - 17:30

Hall N

Chair: Mellar Davis (USA)

Co-Chair: David Hui (USA)

16:00 Introduction

Invited Speaker: David Hui (USA)

16:02 Pathophysiology, Prevalence and Assessment

Invited Speaker: David Currow (Australia)

16:24 Pharmacologic Management: An Evidence-Based Update

Invited Speaker: David Hui (USA)

16:46 Non-Pharmacologic Measures: The Fundamentals

Invited Speaker: Meera Agar (Australia)

**17:08 STRATEGIES FOR ONCOLOGY CLINICIANS
COMMUNICATING WITH FAMILY MEMBERS:
DEVELOPMENT AND DELPHI CONSENSUS EVALUATION**

: Rebekah Laidsaar-Powell (Australia)

**17:18 ENHANCING BEDSIDE NURSES' PALLIATIVE
COMMUNICATION SKILL COMPETENCY: AN EXEMPLAR
FROM THE UNIVERSITY OF CALIFORNIA ACADEMIC
HOSPITALS' QUALITY IMPROVEMENT COLLABORATIVE**

: Deborah BOYLE (USA)

PARALLEL SESSION: Parallel 20: E-poster session: Role of yoga and complementary medicine in maintaining quality of life

16:00 - 17:30

Hall L2

Chair: Jørn Herrstedt (Denmark)

Co-Chair: Sushma Bhatnagar (India)

16:00 Introduction

Invited Speaker: Jørn Herrstedt (Denmark)

16:02 Role of yoga in maintaining quality of Life (QOL) in cancer patients

Invited Speaker: Abhishek Shankar (India)

16:24 Role of CAM in reducing pain and symptoms in cancer patients

Invited Speaker: Sushma Bhatnagar (India)

16:46 Role of CAM in oncology care

Invited Speaker: Goura Kishor Rath (India)

17:08 Effect of YOCAS Yoga, Sleep and Fatigue on Quality of Life (QOL) in Female Breast Cancer Survivors

: Anita Peoples (USA)

- 17:18 **USE OF ALTERNATIVE TREATMENT IN ADDITION TO CONVENTIONAL THERAPY AMONG DANISH CANCER PATIENTS**
: Kristin Ingstrup Nielsen, Medical student (Denmark)

STUDY GROUP/MASCC MEETING: SG8

16:00 - 17:00

Hall L3

e-Poster Discussion: Session 3

16:00 - 17:30

Exhibition

- Chair: Rachel Gibson (Australia)
Co-Chair: Tba Tba ()
- 16:00 **Cardiovascular Disease (CVD) Risk Factors and Health Behaviors after Cisplatin-based Chemotherapy: a Multi-institutional Study of Testicular Cancer Survivors (TCS) in the Platinum Study**
: Mary Brames (USA)
- 16:09 **Sexual health care attitude and practices for cancer patients among clinical nurses and physicians**
: Jung-Hee Kim (Republic of Korea)
- 16:18 **Mobile game for management in metastatic breast cancer patients receiving cytotoxic chemotherapy**
: Hee-Jun Kim (Republic of Korea)
- 16:27 **Effect of Expressive Writing Intervention on Health Outcomes in Breast Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials**
: Chunlan Zhou (China)
- 16:36 **HOW DO I DO THAT AGAIN? VODCASTS FOR PATIENTS WITH FEEDING TUBES AND SWALLOWING DIFFICULTIES**
: Jenelle Loeliger (Australia)
- 16:45 **Is cognition reported by cancer patients different from that reported by patients with neurological conditions?**
: Jin-Shei Lai (USA)
- 16:54 **Fear of cancer recurrence and psychological well-being in women with breast cancer: The role of causal cancer attributions and optimism**
: Jo Anne Dumalaon-Canaria (Australia)
- 17:03 **TREATING FATIGUE IN COLORECTAL CANCER (CC) PATIENTS**
: Panagiotis Heras (Greece)
- 17:12 **Effects of Individual Exercise Education on Decreasing Fatigue and Psychological Distress in Patients in with Colorectal Cancer after Surgery: A Clinical Randomized Control Trial**
: Shiow-ching Shun (Taiwan)

17:21 **EVALUATION OF AN EDUCATION PROGRAM TO
FACILITATE PATIENT ADHERENCE,TOXICITY MONITORING
AND PROMOTE SAFETY AND WELL-BEING IN THE SELF
ADMINISTRATION OF ORAL CHEMOTHERAPY**
: Tina Griffiths (Australia)

SATELLITE SYMPOSIUM: Satellite Symposium
(Industry Session not included in main event CME/CPD credit)

17:45 - 18:45 Hall L

SATELLITE SYMPOSIUM: Satellite Symposium
(Industry Session not included in main event CME/CPD credit)

17:45 - 18:45 Hall M

OTHER: Educational Session: How to write a manuscript for supportive care in cancer (parallel session type)

17:45 - 18:45 Hall N

STUDY GROUP/MASCC MEETING: SG9

17:45 - 18:45 Hall L2

STUDY GROUP/MASCC MEETING: SG10

17:45 - 18:45 Hall L3

Saturday, June 25, 2016

SATELLITE SYMPOSIUM: Satellite Symposium *(Industry Session not included in main event CME/CPD credit)*

08:00 - 09:00

Hall L

STUDY GROUP/MASCC MEETING: SG21

08:00 - 09:00

Hall M

ISOO SESSION: ISOO Session 1: ISOO-EBMT Collaboration - oral oncology and haematopoietic stem cell transplantation, moving on from the basic oral care paper – what is next?

08:00 - 10:30

Hall N

ISOO CE Course and Business Meeting

Chair: Ourania Nicolatou-Galitis (Greece)

ISOO Session 1: ISOO-EBMT Collaboration - oral oncology and haematopoietic stem cell transplantation, moving on from the basic oral care paper - what is next?

Chair: Tba Tba ()

08:10 **Introduction, background (to collaboration) and welcome (ISOO & EBMT)**

Invited Speaker: Richard Logan (Australia)

08:45 **Oral oncology and transplant care - The transplant team perspective**

Invited Speaker: Barry Quinn (United Kingdom)

09:20 **Oral oncology and transplant care - the dental team's perspective**

Invited Speaker: Elvira Correa (Brazil)

09:55 **Panel Discussion**

STUDY GROUP/MASCC MEETING: SG12

08:00 - 09:00

Hall L2

STUDY GROUP/MASCC MEETING: SG13

08:00 - 09:00

Hall L3

PARALLEL SESSION: Parallel 21: Paediatrics (Paediatric study group)

09:00 - 10:30

Hall L

- Chair: Wim Tissing (Netherlands)
Co-Chair: Faith Gibson (United Kingdom)
- 09:00 **Introduction**
Invited Speaker: Wim Tissing (Netherlands)
- 09:02 **Paediatric dentistry as part of an oncology team**
Invited Speaker: Sam Gue (Australia)
- 09:24 **Recent Paediatric guidelines development**
Invited Speaker: Wim Tissing (Netherlands)
- 09:46 **TBA**
Invited Speaker: Faith Gibson (United Kingdom)
- 10:08 **ASSESSMENT OF INVISIBLE FINANCIAL BURDEN FACED BY FAMILIES WITH CANCER CHILDREN IN INDIA**
: AUROSRI RAMACHANDRAN (India)
- 10:18 **Parents' preferences for the organization of long-term follow-up of childhood cancer survivors**
: Janine Vetsch (Switzerland)

PARALLEL SESSION: Parallel 22: e-Poster session

09:00 - 10:30

Hall M

- Chair: Rachel Gibson (Australia)
Co-Chair: Tba Tba ()
- 09:00 **Introduction**
Invited Speaker: Rachel Gibson (Australia)
- 09:02 **Role of Benzydamine Hydrochloride in Prevention of Oral Mucositis in Head and Neck Cancer Patients Treated with Radiotherapy (>50 Gray) with or without Chemotherapy**
: Madhup Rastogi (India)
- 09:12 **SGX942 REDUCES THE DURATION OF SEVERE ORAL MUCOSITIS (OM) IN HEAD AND NECK CANCER (HNC) PATIENTS IN A PHASE 2 PLACEBO-CONTROLLED, DOUBLE-BLINDED RANDOMIZED TRIAL**
: Richard Straube (USA)
- 09:22 **THE IMPACT OF A SIMPLIFIED DOCUMENTATION METHOD FOR THE EDMONTON CLASSIFICATION SYSTEM FOR CANCER PAIN (ECS-CP) ON CLINICIAN UTILIZATION**
: Kimberson Tanco (USA)
- 09:32 **An 'expert' model of compassion: advanced cancer patients perspectives and experiences of compassionate care**
: Shane Sinclair (Canada)
- 09:42 **FACTORS INFLUENCING NUTRITIONAL STATUS AFTER CURATIVE GASTRECTOMY FOR GASTRIC CANCER**
: Tsae-Jyy Wang (Taiwan)

- 09:52 **INTESTINAL MUCOSITIS INDUCED BY 5-FLUOROURACIL RESULTS IN GLIAL CHANGES MODIFIED BY ANALGESICS VIA NEURO-IMMUNE MECHANISMS**
: Juliana Bajic (Australia)
- 10:02 **The Degree of Concordance on End-of-Life Care Decisions Using the Korean Advance Directives among Cancer Patient-Caregiver Dyads**
: Su-Jin Koh (Republic of Korea)
- 10:12 **Evaluating the Utility of the QUAL-EC in the Clinical Care of Patients With Advanced Cancer**
: Anne Wilkinson (Australia)

PARALLEL SESSION: Parallel 23: Toxicity of combined chemotherapy and radiotherapy

09:00 - 10:30

Hall L2

- Chair: Petra Feyer (Germany)
Co-Chair: Tba Tba ()
- 09:00 **Introduction**
Invited Speaker: Petra Feyer (Germany)
- 09:02 **Head and neck**
Invited Speaker: Barbara Murphy (USA)
- 09:19 **Lung**
Invited Speaker: David Ball (Australia)
- 09:36 **Prostate Cancer**
Invited Speaker: James Denham (Australia)
- 09:53 **Basic Research**
Invited Speaker: Eva Bezak (Australia)
- 10:10 **The prevalence and severity of drug interactions in hospitalized and ambulatory cancer patients**
: Ayberk Besen (Turkey)
- 10:20 **IDENTIFICATION OF BIOMARKERS OF CHEMORADIOTHERAPY-INDUCED TOXICITY IN UPPER GASTROINTESTINAL CANCERS**
: Imogen Ball (Australia)

PARALLEL SESSION: Parallel 27: Hair loss and scalp cooling: integrating state of science into practice

09:00 - 10:30

Hall L3

- Chair: Tba Tba ()
Co-Chair: Fran Boyle (Australia)
- 09:00 **Introduction**
Invited Speaker: Jane Bryce (Italy)
- 09:02 **TBA**
Invited Speaker: Fran Boyle (Australia)
- 09:24 **TBA**
Invited Speaker: Corina Van den Hurk (Netherlands)
- 09:46 **TBA**
Invited Speaker: Hope Rugo (USA)

- 10:08 **EYELASH AND EYEBROW MADAROSIS: A QUALITATIVE STUDY TO ASSESS THE PERCEPTIONS AND EXPERIENCE OF AUSTRALIAN PATIENTS WITH BREAST CANCER**
: Kortnye Morris (Australia)
- 10:18 **Comfortable cooling device versus Nature**
: Java Walladbegi (Sweden)

e-Poster Discussion: Session 4

09:00 - 10:30

Exhibition

- Chair: Jørn Herrstedt (Denmark)
Co-Chair: Tba Tba ()
- 09:00 **Prevalence of and factors associated with sarcopenia in Korean cancer survivors: Based on data obtained by Korea National Health and Nutrition Examination Survey (KNHANES) 2008-2011**
: Eun Young Kim (Republic of Korea)
- 09:09 **Skeletal muscle depletion and relationship to survival in non-small cell lung cancer patients receiving chemo-radiation**
: Nicole Kiss (Australia)
- 09:18 **INTER-RATER RELIABILITY OF NUTRITIONAL ASSESSMENT TOOLS IN THE ONCOLOGY SETTING**
: Abigail Villanueva (Australia)
- 09:27 **OCCUPATIONAL RISK OF EXPOSURE TO CYTOSTATIC DRUGS**
: Maria Kiagia (Greece)
- 09:36 **Prognostic significance of CT-determined emphysema in patients with small cell lung cancer**
: Young Saing Kim (Republic of Korea)
- 09:45 **Vertebroplasty in patients with prostate cancer raises specific subtypes of skeletal complications.**
: Guilhem Roubaud (France)
- 09:54 **INDIVIDUAL VS. DYADIC INTERVENTION TO INCREASE PHYSICAL ACTIVITY AND REDUCE DEPRESSION AND ASSOCIATED INFLAMMATION AMONG LESBIAN, GAY, AND HETEROSEXUAL CANCER SURVIVORS AND CAREGIVERS**
: Charles Kamen (USA)
- 10:03 **DYADIC INTERDEPENDENCE IN PSYCHOSOCIAL OUTCOMES AND THE ROLE OF UNMET NEEDS AMONG PATIENTS WITH HAEMATOLOGICAL CANCERS AND THEIR SUPPORT PERSONS**
: Christine Paul (Australia)
- 10:12 **Exercise Decreases Depression and Improves Quality of Life in Cancer Survivors with Elevated Depressive Symptomatology**
: Gregory Levin (Australia)
- 10:21 **THE ASSOCIATION OF PATIENT CHARACTERISTICS WITH DERMATOLOGIC TOXICITY SEVERITY IN PATIENTS TREATED WITH PANITUMUMAB AND FOLFOX OR FOLFIRI**
: Timothy Price (Australia)

PARALLEL SESSION: Parallel 25: Thinking and talking about survival time in advanced cancer

11:00 - 12:30

Hall L

- Chair: Belinda Kiely (Australia)
Co-Chair: Stockler Martin (Australia)
- 11:00 **Introduction**
Invited Speaker: Belinda Kiely (Australia)
- 11:02 **Update on patient preferences for prognostic information**
Invited Speaker: Phyllis Butow (Australia)
- 11:27 **Teaching communication skills regarding prognosis to Australian oncology trainees**
Invited Speaker: Fran Boyle (Australia)
- 11:52 **Using a web-based tool to estimate and explain 3 scenarios for survival time to patients with advanced cancer**
Invited Speaker: Belinda Kiely (Australia)
- 12:17 **AN INVESTIGATION OF THE CONCORDANCE BETWEEN PATIENTS AND THEIR NON-PROFESSIONAL CARERS ABOUT FACTORS ASSOCIATED WITH A “GOOD DEATH” AND OTHER IMPORTANT END-OF-LIFE DECISIONS**
: Andrew Davies (United Kingdom)

PARALLEL SESSION: Parallel 26: e-Poster session

11:00 - 12:30

Hall M

- Chair: Jørn Herrstedt (Denmark)
Co-Chair: Tba Tba ()
- 11:00 **Neurophysiological Changes Associated with Sunitinib Fatigue Severity**
: Mellar Davis (USA)
- 11:09 **Compassion Fatigue, Burnout, and Compassion Satisfaction among Oncology Nurse Within an International Setting**
: Savitri Singh-carlson (USA)
- 11:18 **Patient initiated mentoring program in kidney cancer: Preliminary Outcomes**
: Winston Tan (USA)
- 11:27 **COMMUNAL COPING IN FAMILIES AT RISK OF LYNCH SYNDROME.**
: Laura Koehly, Senior Investigator (USA)
- 11:36 **Quality of life, efficacy and patient-reported outcome with NEPA as CINV prophylaxis in highly or moderately emetogenic chemotherapy**
: Joerg Schilling (Germany)
- 11:45 **Rolapitant for control of chemotherapy-induced nausea and vomiting (CINV) in patients with lung cancer**
: Rudolph Navari (USA)
- 11:54 **PROPHYLAXIS OF RADIATION-INDUCED NAUSEA AND VOMITING: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS**
: Wing Sum Li (Hong Kong, China)
- 12:03 **Rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer**
: Lee Schwartzberg (USA)
- 12:12 **Informed consent in cancer care - a study of Victorian patients' experiences**
: Deborah Lawson (Australia)

- 12:21 **SUBGROUPS OF PATIENTS WITH DISTINCT PAIN QUALITIES ASSOCIATED WITH CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY (CIPN)**
: Christine Miaskowski (USA)

ISOO SESSION: ISOO Session 2: From silos to symptom clusters: 30 years of the ISOO

11:00 - 12:30

Hall N

- ISOO Session 2: From silos to symptom clusters: 30 years of the ISOO**
Chair: Nair Raj (Australia)
- 11:00 **Symptom clusters - an oral oncology perspective**
Invited Speaker: Doug Peterson (USA)
- 11:25 **A medical oncology perspective on how understanding of our symptoms affects management of patients**
Invited Speaker: Barbara Murphy (USA)
- 11:50 **A radiation oncology perspective on how our understanding of symptoms affects management of patients**
Invited Speaker: John Wu (Canada)
- 12:15 **Panel Discussion: (15 min.)**

PARALLEL SESSION: Parallel 24: Challenges and solutions for cancer related fatigue

11:00 - 12:30

Hall L2

- Chair: Karen Mustian (USA)
Co-Chair: Sriram Yennu (USA)
- 11:00 **Introduction**
Invited Speaker: Karen Mustian (USA)
- 11:02 **The impact of cancer associated inflammation on cachexia, cancer prognosis and outcomes**
Invited Speaker: Stephen Clarke (Australia)
- 11:19 **Exercise prescription for cancer-related fatigue: what's the optimal dose?**
Invited Speaker: Karen Mustian (USA)
- 11:36 **Is there a role for psychostimulants in the management of CRF**
Invited Speaker: Fausto Roila (Italy)
- 11:53 **Personalized therapy in CRF: Targeting mechanisms, role of corticosteroids, cognitive behavioral therapy or combination therapy**
Invited Speaker: Sriram Yennu (USA)
- 12:10 **POOLED EFFICACY DATA FROM ROMANA 1 AND ROMANA 2, TWO PHASE 3 TRIALS OF ANAMORELIN IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH CACHEXIA**
: David Currow (Australia)
- 12:20 **Fatigue is Associated with Impairments in Instrumental Activities of Daily Living (IADL) and Decreased Physical Performance in Older Cancer Patients**
: Marie Flannery (USA)

PARALLEL SESSION: Parallel 28: Palliative care pain management

11:00 - 12:30

Hall L3

- Chair: Mellar Davis (USA)
Co-Chair: Tba Tba ()
- 11:00 **Introduction**
Invited Speaker: Mellar Davis (Ireland)
- 11:02 **Scrambler therapy in managing cancer pain; what is the evidence?**
Invited Speaker: Charles Loprinzi (USA)
- 11:24 **Managing pain in a cancer survivor**
Invited Speaker: Paul Sloan (USA)
- 11:46 **Chemotherapy neuropathy, conditioned pain modulation and the benefits of quantitative sensory testing and duloxetine**
Invited Speaker: Mellar Davis (Ireland)
- 12:08 **Phase III randomized double-blind controlled trial of oral risperidone, haloperidol or placebo with rescue subcutaneous midazolam for delirium management in palliative care**
: Meera Agar (Australia)
- 12:18 **DEXAMETHASONE FOR DYSPNEA IN CANCER PATIENTS: A DOUBLE-BLIND, RANDOMIZED CONTROLLED TRIAL**
: David Hui (USA)

PLENARY SESSION: Plenary 3: Survivorship

13:00 - 14:30

Hall M

- Chair: Dave Warr (Canada)
Co-Chair: Bogda Koczwara (Australia)
- 13:00 **Introduction**
Invited Speaker: Dave Warr (Canada)
- 13:02 **Cancer survivorship: moving from risk to risk reduction**
Invited Speaker: Kevin Oeffinger (USA)
- 13:31 **Older survivors: placing cancer well among other health issues**
Invited Speaker: Martine Extermann (USA)
- 14:00 **Social determinants of health in cancer and chronic disease and their implications for cancer in disadvantaged populations: Fran Baum, Australia (30 min)**
Invited Speaker: Fran Baum (Australia)

ISOO SESSION: ISOO Session 3: Oral care study group guidelines update (including a launch of patient care guidelines)

13:00 - 15:00

Hall N

- Chair: Richard Logan (Australia)
- 13:00 **Does hyperbaric oxygen have a role in preventing osteoradionecrosis post-radiotherapy?**
Invited Speaker: Allan Hovan (Canada)
- 13:30 **Photobiomodulation using low level laser therapy in supportive care in cancer: are we ready yet?**
Invited Speaker: Nair Raj (Australia)
- 14:10 **ISOO Patient Care Information**
Invited Speaker: Deborah P. Saunders (Canada)

OTHER: Closing Ceremony

14:30 - 15:00

Hall M

STUDY GROUP/MASCC MEETING: SG14

15:00 - 16:00

Hall M

STUDY GROUP/MASCC MEETING: SG15

15:00 - 16:00

Hall N

STUDY GROUP/MASCC MEETING: SG16

15:00 - 16:00

Hall L2

STUDY GROUP/MASCC MEETING: SG17

15:00 - 16:00

Hall L3